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Abstract 
 
 
 
In spite of great effort aimed at eradication, the malaria epidemic still claims over 
600,000 lives each year, and 50% of the world is at risk of contracting the disease.  The 
most deadly form of malaria is caused by Plasmodium falciparum, which is spread from 
human to human via the female Anopheles mosquito.  P. falciparum’s lifecycle, which 
includes both sexual and asexual reproduction, facilitates rapid evolution in response to 
drug pressure, resulting in the emergence of resistant strains against every antimalarial 
medication that has been deployed.  There is a great need for new antimalarial drugs. 
Chloroquine (CQ), an aminoquinoline drug deployed in the 1940s, was an 
inexpensive, effective and safe drug but now has been rendered ineffective throughout 
much of the tropical regions due to the emergence of CQ-resistant strains of P. 
falciparum. A new class of hybrid drugs, called Reversed-CQs, has been developed by 
linking a molecule with a CQ-like moiety to a molecule with a reversal agent (RA) 
moiety; an RA is a chemosensitizer that can reverse CQ-resistance. The prototype 
Reversed-CQ, PL01, was shown to be effective in vitro against sensitive and resistant P. 
falciparum cell cultures, with IC50 values of 2.9 and 5.3 nM, respectively, in comparison 
to IC50 values for CQ which were 6.9 and 102 nM, respectively. 
In the course of the Reversed-CQ research, PL74 was synthesized with a pyridine 
ring replacing the quinoline ring.  It was expected that PL74 would display reversal agent 
activity but would not display antimalarial activity.  However PL74 showed antimalarial 
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activity with IC50 values of 185 and 169 nM in vitro against CQ-sensitive and CQ-
resistant strains, respectively.  In the investigation of PL74 it has been found that this 
molecule has a pyridinium salt structure, novel to the Reversed-CQ compounds, and 
through a structure-activity relationship (SAR) study, it was shown to have activity that 
may indicate a mode of action different from the Reversed-CQ compounds. A study of 
the literature revealed that pyridinium salt compounds, with some similarity to PL74, 
were found to operate as choline analogs inhibiting the biosynthesis of 
phosphatidylcholine as their main antimalarial mode of action.   
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Chapter 1 
 
Introduction 
 
Malaria is a worldwide problem causing approximately 200 million cases of 
illness, resulting in over 600,000 deaths per year.1  The majority of this disease burden is 
borne by the sub-Saharan Africa population, and the majority of the global malaria 
mortalities are among the children of this region.  Nearly 50% of the world’s population 
is currently at risk of contracting malaria.1  These statistics show a marked improvement 
in the mortality rate from the estimated one million deaths per year from 2000 to 2005.1   
However, an analysis of the mortality rates by Christopher Murray and his team at the 
Institute for Health Metrics and Evaluation, University of Washington, found that the 
death toll due to malaria has been about twice the estimates reported by the World Health 
Organization (WHO) for the years of 1980-2008; thus the 2013 WHO statistics may be 
an understatement of the situation.2  
 Malaria has a catastrophic effect on the economics of the endemic regions, 
severely hindering social stability and development.3  Malaria and extreme poverty form 
a vicious cycle: Malaria causes extreme poverty by causing an unreliable workforce and 
deterring investments in the region; extreme poverty makes it impossible to fight 
effectively against malaria because of the high costs of public education, vector control, 
and treatment.  In this way malaria is a history shaper, so it is not coincidental that the 
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map of malaria disease burden is the approximate inverse of the map of the distribution 
of wealth (Figure 1.1). 
 
Figure 1.1:  The Inverse Relationship of Malaria Burden to Wealth Distribution    
Map of Malaria Risk (Top).   
The Global Malaria Mapper plotted March, 2014, http://www.worldmalariareport.org. 
Map of Gross Domestic Product Per Capita (Bottom). 
GDP data from 2005, http://commons.wikimedia.org 
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The most alarming part of the malaria situation is that the drugs and insecticides 
that have been useful in the past against malaria are losing their effectiveness due to the 
development of resistance in both the malaria parasite and the Anopheles mosquito,  
which serves as the vector of disease transmission.  There is a need for a constant supply 
of new tools and thoughtfulness in their use to bring this epidemic under control and 
perhaps to the eventual eradication of malaria.  
 
Background  
Plasmodium protozoa are the causative parasitic organisms of malaria.4  There are 
over 120 different species of Plasmodia, but only five types of malarial parasites (P. 
falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi) are commonly found in 
humans.4,5  P. falciparum, the most virulent of the five, is the most studied form of 
malaria, and the target of this research. 
 The onset of malaria is generally characterized by flu-like symptoms: fever, 
shaking chills, headache, sweats, fatigue, nausea, and vomiting.6  The signature symptom 
of a malaria infection is that the febrile symptoms occur in a cyclic pattern.  However, 
most adults in endemic regions remain asymptomatic during malaria infections.7  
Untreated or improperly treated P. falciparum malaria may lead to kidney failure, mental 
confusion, coma, pulmonary edema, and death.6 
P. falciparum is spread from human host to human host exclusively via the female 
Anopheles mosquito.8,9  The Anopheles mosquitoes are nocturnal insects that breed in 
standing water, then emerge as fully developed adults within days,9 and mate within one 
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to two days after emergence.10  The female will lay 50 to 200 eggs within two to three 
days in tropical climates.10  The female requires blood meals during the egg maturation 
process, in which it may ingest the malaria parasite from an infected human or transmit 
the parasite.   
The lifecycle of P. falciparum (Figure 1.2) requires both a female Anopheles 
mosquito host and human host, and includes both sexual and asexual reproduction.  
When an infected female Anopheles mosquito bites a human, P. falciparum sporozoites 
 are released from the mosquito’s salivary glands into the bloodstream of its victim.8  
Within a few minutes the sporozoites enter the liver and invade the hepatocytes.  The 
parasites undergo asexual multiplication in the liver cells, increasing to tens of thousands 
over 9 to 16 days, then burst from the liver cells and invade the erythrocytes.  The 
sporozoites undergo further asexual multiplication in the erythrocytes – resulting in 12-16 
merozoites from each sporozoite, eventually rupturing the cells and invading other 
erythrocytes.  This erythrocytic stage cycles every 48 hours for P. falciparum, P. vivax 
and P. ovale; every 72 hours for P. malariae; and every 24 hours for P. knowlesi.7,11  In 
response to this periodic rupturing, the host’s immune system causes the cyclic fevers and 
chills which are the signature clinical manifestations of malaria infections.  Some of the 
merozoites differentiate into male and female gametocytes but remain in an immature 
form while in the human host.  However, if these gametocytes are taken up as a female 
Anopheles mosquito takes a blood meal and enter the gut of the mosquito, the male 
gametocyte is able to mature and fertilize the female gametocyte, creating an oocyte 
which may be the beginning of a new strain of P. falciparum.  Within the oocyte, 
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sporozoites are formed by asexual reproduction.  The oocyte will eventually burst open 
and release the sporozoites.  These sporozoites migrate to the salivary glands of the 
mosquito and are released into human hosts during blood meals.  Parasite development in 
the mosquito, from the time of ingestion to transmission, is 10 to 21 days.9  
Figure 1.2: Malaria Lifecycle 
Repurposed graphic combining figure from Malaria Vaccine Initiative (www.malariavaccine.org) and 
picture by Mr. Stephen Morrison (European Press Agency) 
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 When the human host takes an antimalarial drug during the life cycle of the 
parasite, the hope is to kill all the parasites and thereby end the malaria sickness.  
However, if the drug is not potent enough, or if it is not taken over a long enough time, a 
few parasites may survive, some of which might happen to have a variation in their 
genome that gives them an enhanced ability to survive and continue to replicate, allowing 
the emergence of new strains.  When the genomes of those survivors are crossed with the 
genomes of other survivors during sexual reproduction, new parasites with adaptations 
that can withstand the antimalarial action of a drug may emerge.  When sufficient and 
widespread resistance has emerged against a specific drug, then that drug is deemed no 
longer useful in that area.  
 
Strategies for Control 
In developing a strategy to control and eventually eradicate malaria, three areas of 
response emerge: vector controls, vaccines, and antimalarial drugs.1  No one method of 
the control is adequate, but efforts in all three areas are reducing the number of deaths 
due to malaria. 
Vector Controls:  There are over 40 species of Anopheles mosquitos that have the 
abundance, longevity, capacity and preference for human blood to make them a 
significant threat.12  Among these species there are diverse habitat and feeding 
requirements, making it difficult to find just one single answer to control the mosquito 
populations.  Several approaches are in use to reduce the mosquito populations including 
eliminating or treating standing water to lessen the available breeding grounds for larva.  
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Such treatments include the introduction of larva-eating fish or treating the waters with 
Bacillus thuringiensis isrealensis and Bacillus sphaericus, bacterial pathogens selective 
for mosquito larva.12  Insecticides are employed to reduce the adult population of 
mosquitoes, however, the mosquitos are developing resistance to the insecticides so that 
they are becoming less potent over time.12 
An obvious way to interrupt the malaria transmission cycle is to keep mosquitoes 
from biting humans.  A way to accomplish this goal is by protecting humans with 
insecticide treated bed nets (ITNs), especially during the nighttime when the Anopheles 
mosquitoes are most active.  When surveying populations at risk, it was self-reported that 
55% of households own at least one ITN, 33% own an adequate number to protect all the 
members of the household, and 86% of ITN owners diligently use them.1  The WHO 
estimates, admittedly crudely, that there are over 300 million ITNs currently in service, 
but at least 450 million are needed for adequate coverage.1  The useful life expectancy of 
an ITN is three years; one third of the ITNs retiring each year makes it difficult to build 
to the needed level of availability.1  The use of ITNs has been shown to reduce mortality 
rates for children (under the age of 5) by approximately 16%, in a 2002 study in western 
Kenya.13  Even with such a remarkable achievement, vector controls alone are not 
adequate to control, eliminate, or eradicate malaria. 
Vaccines:  A vaccine against malaria would be a very useful tool to combat 
malaria in endemic areas.  Vaccines ideally educate the immune system to provide long-
term immunity against disease.  Although several successful vaccines have been 
produced against viruses such as smallpox and measles, the antimalarial vaccines that are 
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now in human trials are the first vaccines that have been produced with a degree of 
success against any parasite.  As discussed next, the success is modest. 
A vaccine against a parasite is more challenging than an antiviral vaccine because 
the parasite potentially presents thousands of antigens to the human immune system, 
changes forms throughout its life stages in the human host, evolves to render the immune 
responses ineffective (as do viruses), and spends much of its lifecycle inside host cells.14  
On the other hand, there are indicators that a malaria vaccine may be feasible: the 
occurrence of natural immunities developed in response to severe disease, the finding that 
irradiated sporozoites introduced into humans provided some protection from subsequent 
challenges, and the finding that immunity can be passively transferred by injecting 
antibodies from a host that has acquired immunity.14,15 
A notable accomplishment of the vaccine research to date is the Glaxo Smith 
Kline RTS,S/AS01, a vaccine candidate that acts against liver stage malaria.  In Phase III 
clinical trials, RTS,S/AS01 has shown to reduce the incidence of clinical disease by 55% 
for the year following vaccination.1,16  
The PfSPZ vaccine comprised of non-replicating, whole P. falciparum 
sporozoites being developed by Sanaria has recently completed a Phase I clinical trial; 
the early findings show that the vaccine was well tolerated by the study participants, and 
that 12 out of 15 were protected from a challenge infection administered three weeks 
later.15  Although these results look promising, the cost and time investment to produce 
whole organism vaccines makes this a less desirable vaccine for widespread use.17 
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Pfs25-EPA is a transmission-blocking vaccine that acts against antigens expressed 
on the surface of the gametocyte, the sexual form of the parasite that remains in the blood 
stream.18,19  When the gametocyte is taken up by the mosquito it is unable to reproduce. 
The drawback of this approach is that it carries no direct protective benefit for the 
vaccinated person and requires widespread employment before any benefit would be 
realized. 
There are several other vaccine candidates that are being pursued that are much 
earlier in the development process; they are estimated to be five to ten years away from 
clinical trials.1  Among these candidates are blood stage infection and transmission 
blocking vaccines, all showing promise of usefulness.1  However, even after decades of 
research and development, we still do not have a vaccine that is ready for widespread use.  
Our inability to eradicate the mosquito vector quickly, or to develop a wide-spectrum, 
long-lasting vaccine quickly leaves us with the alternative of fighting pandemic active 
infections with chemotherapeutic drugs.   
Antimalarial Drugs:  Quinine (Figure 1.3), an extract from Cinchona bark, has 
served as a leading antimalarial for hundreds of 
years.20  It was used in the unextracted form 
since the 1600s, and was isolated and named in 
1817 by French researches Pierre Pelletier and 
Joseph Caventou.  In 1964, Robert Woodward 
and coworkers achieved the first total synthesis 
of quinine.21,22  Quinine was very effective for Figure 1.3:  Structure of Quinine 
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the treatment of malaria caused by P. falciparum, and it remained the frontline drug until 
the 1940s when chloroquine (CQ) took over.  Although quinine is effective, it has many 
unpleasant, but usually temporary, side effects.  It causes sweatiness, tinnitus, vision 
problems, hearing impairment, confusion, headaches, rashes, abdominal pain, 
photosensitivity, vertigo, dysphoria, nausea, vomiting, and diarrhea.20 
 In 1946, CQ (Figure 1.4) was introduced as an antimalarial.  CQ was synthesized 
and studied as an antimalarial beginning in 1934 by Hans Andersag at Bayer I.F. 
Farbenindustrie A.G. Laboratories in Eberfeld, Germany.23  However, CQ was  
abandoned in favor of Atabrine, 
another drug candidate, because of 
its slight toxicity in birds, and so CQ 
was overlooked until 1946 when it 
was recognized for its safe and 
effective antimalarial properties by 
British and US scientists.  CQ 
quickly became the main drug used for malaria treatment and prevention because it was 
effective in a few doses, had mild side effects, was safe even for infants and pregnant 
women, and was very inexpensive.  It was hoped that this drug, along with mosquito 
control, would be the means to eradicate the disease worldwide.  However, by the 1950s 
CQ-resistant strains of malaria emerged in South America and Southeast Asia, then 
quickly spread throughout the world except for Africa.  In the 1980s CQ-resistant strains 
began to emerge in Africa.  Although still used in Africa, CQ has been rendered nearly 
Figure 1.4:  Structure of Chloroquine (CQ) 
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ineffective in much of the world, and its continued use will certainly promote the 
evolution of CQ-resistant strains of P. falciparum malaria.  Discussion of the CQ mode of 
action and mechanism of resistance is deferred to a later section of this chapter. 
 Artemisinin (Figure 1.5), the current lead antimalarial, is a sesquinterpene lactone 
with a peroxide bridge.  Artemisinin is isolated from the plant, Artemisia annua, and has 
been known in traditional Chinese medicine for thousands of years.  The earliest mention 
of its use dates back to 168 B.C., but the first mention of its use as an antimalarial was by 
Wenbing Tiaohian in 1798.24  It was forgotten, then rediscovered in 1972 by Tu Youyou, 
who was evaluating traditional Chinese 
medicines for treating malaria.24  The 
practical use of artemisinin as an 
antimalarial agent is impaired by its 
insolubility in both water and oil, poor 
efficacy by oral administration, and the rate 
of recrudescence in treated patients.  To 
improve solubility and bioavailability, semi-
synthetic analogs were devised.  Three that are currently in use are artemether, artesunate, 
and dihydroartemisinin (Figure 1.6).  The artemisinins are very potent antimalarials that 
are effective against both sexual and asexual forms of the parasite; in addition, they are 
very fast acting drugs, killing the malaria parasite within minutes and clearing the blood 
of 98% of infection with a single dose.  However, artemisinins have very short half-lives 
Figure 1.5:  Structure of Artemisinin 
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in the body, which makes it difficult to dose for continuity of coverage over a span of the 
parasite’s lifecycle.25    
The mode of action for the artemisinins is still under investigation.  It is known 
that the peroxide bridge is essential to the activity of the artemisinins: when one peroxide 
Figure 1.6:  Structures of Artemisinin-Based Combination Therapies (ACTs) 
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oxygen is replaced by a carbon, the resulting analog is inactive.26  The mode of action of 
the artemisinins is via a free radical mechanism, shown by the fact that free radical 
scavengers have an antagonistic effect on the antimalarial activity of these drugs.27,28  
Free iron and/or heme-bound iron activate the homolytic cleavage of the endoperoxy 
bridge of the artemisinins to form a radical.  The need for an iron-rich environment for 
activation may be the reason that this drug acts selectively against the parasite.  The free 
radical may act as an oxy radical or rearrange to a carbon centered radical.29  Several 
possible actions of the radical have been suggested, including acting as a strong reducing 
agent, alkylating heme, and/or alkylating proteins.30  
Because of the increasing problem of resistance against antimalarial therapies, the 
WHO recommended in 2005 that all countries experiencing P. falciparum drug resistance 
use drugs in combination therapies, preferably artemisinin-based combination therapies 
(ACTs).31  The rationale for ACTs is that it combines drugs with different modes of 
action against the same parasite life stage, making it statistically improbable that mutant 
strains would develop resistance mechanisms at both sites of action, thereby killing more 
(or all) of the parasites of an infection, and thereby protecting against the development of 
resistance to either of the drugs.   
In the design of an ideal combination therapy there are several pharmacodynamic 
and pharmacokinetic factors to consider.  It is important that these drugs be synergistic 
(or at least non-antagonistic), and have different modes of action against the same life 
stage, providing a parasite killing efficacy of nearly 100% per cycle.32  It is important that 
the drugs are a good pharmacokinetic match so that they both keep constant pressure on 
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the parasite during the whole course of treatment in order to protect both drugs against 
the development of resistance.  The combination needs to be delivered in a simple 
regimen to facilitate patient compliance, and ideally be able to maintain a therapeutic 
level for 3 cycles, which is 6 days for P. falciparum malaria.  It is also preferred that the 
partner drugs have moderate half-lives so the time the drugs reside in the patient at sub-
therapeutic levels is minimized, reducing the opportunity for resistance to develop.  
The ACTs that are currently in use are artemether/lumefantrine, 
artesunate/amodiaquine, artensunate/mefloquine, artensunate/sulfadoxine-
pyrimethamine, and  dihydroartemisinin/piperaquine (Figure 1.6).  Lumetantrine, 
amodiaquine, mefloquine and piperaquine are active against the erythrocytic stages.  The  
modes of action for these drugs are not fully elucidated, but all are suspected to inhibit 
hemozoin formation, much like CQ, discussed below.33  The sulfadoxine-pyrimethamin 
have a well- defined mode of action: inhibiting the enzymes involved in parasitic folic  
acid synthesis.34  These partner drugs all have half-lives longer than the artemisinins.33  
In spite of the precaution of a policy of combination therapy, P. falciparum strains 
that are resistant to the artemisinins have emerged both in the Cambodia-Thailand border 
and at the Northern Thailand-Myanmar border.35  Artemisinin resistance is so far defined 
by the slow clearing of the parasites and is specifically related to the ring-stage parasite.35  
These first signs of resistance are quite alarming in the absence of another lead drug to 
replace the artemisinins as the next cornerstone of malaria chemotherapy.  In addition, 
resistance has emerged to each of the partner drugs currently used in combination with 
the artemisinins. 
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In addition to the curative therapies, intermittent preventive therapy (IPT) is used 
to protect the populations that are most at risk from malaria.  These populations are 
pregnant women, infants, and children, in high transmission areas.  The risk of severe P. 
falciparum malaria is increased for pregnant women and associated with a mortality rate 
of nearly 50%.7  At the time of giving birth, there is evidence of malaria in 25% of the 
women.36  The incidence of babies with low birth weight is twice that of births for non-
infected mothers and the incidence for infant mortality is markedly increased for low 
birth weight babies.36  Seventy percent of the annual death toll for malaria is comprised 
of children that are under the age of 5 years old in high transmission areas.1 
The combination of sulfadoxine-pyrimethamine has been the IPT of choice since 
the mid-1990s.37  Several IPT studies from since the mid-1990s to 2008 have shown 
decrease in both the incidence of malaria and the mortality rate for stable and seasonal 
high transmission areas.36-41  However, studies over the last 10-12 years, in Malawi, 
Tanzania, Uganda and Mozambique all show the lessening or loss of benefit from IPT 
with sufladoxine-pyrimethamine because of the growing resistance against the drugs.37,40 
Another need for prophylactic drugs is among travelers who will be going into 
high transmission areas.  It is estimated that currently there are over a billion international 
border crossings per year.42  It is important to protect travelers for their sake, but with 
such a high volume of travelers it also important to keep malaria from spreading to new 
areas. 
16 
 
A wider range of drugs is available to travelers than can be used in the endemic 
countries based both on the cost and the pharmacokinetics of the drug.  Prophylactic 
drugs currently in use are shown in Figure 1.7.43,44  Travelers have the advantage of being 
able to both build to and wane from therapeutic levels while they are not under the threat 
of malaria infection; malaria infections that occur when drugs are at a sub-therapeutic 
level breed resistance to the drug.  The causal malaria prophylactic drugs act against the 
liver-stage of the 
parasites lifecycle and 
the suppressive drugs 
act against the blood 
stage of the parasite.45    
The drug choice and 
regimen are customized 
to each traveler based 
on the details of their 
itinerary and the 
availability of 
immediate medical 
support during their trip.  The drugs are continued for one to three weeks after exiting the 
endemic regions to facilitate total clearance of the parasite.  Even with a customized 
regimen and good compliance, prophylactic drugs are only 75 - 95% effective for no 
incidence of malaria  infection.44 
Figure 1.7:  Prophylactic Drugs for Travelers  
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A Closer Look at Chloroquine Mode of Action, and Resistance to Chloroquine 
During the blood stage of malaria, P. falciparum imports and digests 60-80% of 
the hemoglobin from the cytoplasm of the host’s red blood cell.46  The four embedded 
heme groups in hemoglobin are freed and cannot be degraded by the parasite.  The 
accumulation of free heme in the digestive vacuole (DV) would be fatally toxic to the 
parasite.47  To avoid the toxic effects, the free heme is crystallized into insoluble, densely 
packed hemozoin, as shown in Figure 1.8. 
 The mechanism for hemozoin formation is not fully understood.  Studies of the in 
vitro formation of β-hematin, a compound that is spectrometrically and 
crystallographically the same as hemozoin and thus presumed to be identical to 
hemozoin,47 have shown the following:  Nucleation of β-hematin occurs spontaneously at 
physiological temperature and acidic pH of the DV but at a rate too slow to be effective 
as the detoxification pathway.48  It has been found that both histidine rich protein and 
lipids promote the nucleation of β-hematin.48  Once nucleation has occurred, the β-
hematin formation process is autocatalytic.47  
Recently it was discovered that lipid nanospheres are present in the DV49 and they 
are the site of hemozoin formation.50,51  Further studies have shown that a two-phase 
system, such as octanol-water or pentanol-water, promotes hemozoin formation over the 
rates seen in water alone, and over the rates seen in octanol or pentanol alone.47  This 
suggests that the interface of the two-phase system catalyzes the formation of hemozoin. 
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 The currently-accepted mode of action of CQ is the inhibition of hemozoin 
formation, thus subjecting the parasite to the toxic effects of the free heme.52  CQ has two 
protonatable nitrogens; the quinolyl nitrogen has a pKa of 9.8 and the tertiary sidechain 
nitrogen has a pKa of 8.6.53  CQ in the uncharged state is membrane-permeable and 
diffuses into the parasite’s DV (Figure 1.9).52  In the acidic DV the CQ becomes doubly 
charged and complexes with the free heme.54  Both the high proton concentration and the 
free heme shift the equilibrium toward CQ in the DV.54  CQ accumulates in the DV to 
approximately 6000 times more than the concentration in uninfected red blood cells.55  
Figure 1.8: Structure of Hemozoin 
Molecular and Biochemical Parasitology 2008, 157, 128 
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Through cell fractionation methods measuring the iron and hemozoin concentrations, it 
has been shown that there is a dose-dependent inhibition of hemozoin formation by CQ, 
which results in the buildup of free heme in the malaria cell and tightly correlates to the 
parasite death.56  Also, tunneling electron microscope images show the disruption of 
hemozoin crystallization by CQ.56  Thus, CQ complexing with heme inhibits the 
biocrystallization of hemozoin, which results in the parasite’s death.  
In CQ-resistant strains of P. falciparum, it has been shown that CQ accumulation 
is four to ten times less in the DV of the parasites than for CQ-sensitive strains.57  From 
comparisons between CQ-resistant and CQ-sensitive strains, it was determined that the 
primary determinants of CQ-resistance are mutations in the pfcrt gene.58  The pfcrt gene 
gives rise to the PfCRT (Plasmodium falciparum CQ resistance transporter) protein, and 
Figure 1.9:  Chloroquine Accumulation 
Graphic inspired by Hladky, S. B. Chloroquine Accumulation, http://www.phar.cam.ac.uk, 2006. 
pKa values from Journal of Medicinal Chemistry, 2008 June 26; 51(12): 3466.  
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has been shown to transport CQ out of the digestive vacuole.59  The PfCRT protein has 
been shown to be located in the DV membrane, and is predicted to have 10 
transmembrane domains.60 
 
Reversal Agents 
  A reversal agent (RA) is a drug that reverses the effect of resistance against 
another drug.61  Because of similarities seen in the resistance of P. falciparum and 
neoplastic cells, the possibility of reversing the resistance was pursued.59  Verapamil, a 
calcium channel blocker, had been useful in reversing drug resistance in neoplastic cell 
cultures by inhibiting the active efflux of anticancer drugs.  When Verapamil was co-
administered with CQ, the IC50 of CQ against CQ-resistant strains was reduced to nearly 
the IC50 of the CQ-sensitive strain.59 
 Several reversal agents 
have been found for P. 
falciparum, and from these 
known reversal agents, a 
geometric distribution map of 
their common chemical features 
was determined through 
modeling studies (Figure 1.10).62  
This three-dimensional map, or 
pharmacophore, based on the 
Figure 1.10: Pharmacophore of Reversal Agents  
Journal of Chemical Information and Modelling 2002, 42, 
 (5),1214 
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specific set of reversal agents was comprised of two aromatic hydrophobic sites and a 
hydrogen bond acceptor site (generally a nitrogen atom located on a side chain two to 
three bonds removed from the aromatic sites).62  This pharmacophore can be applied as a 
predictor of reversal agent potency for analogous molecules.  
 Although the demonstration that reversal agents can restore the effectiveness of 
CQ was encouraging, using reversal agents as part of a treatment regimen has a major 
drawback.  The known antimalarial reversal agents are usually drugs designed for non-
antimalarial purposes.  For example, there are several examples of reversal agents that are 
antihistamines, anti-depressants, anti-hypertensives, or anti-psychotics.  Because these 
drugs were designed to affect other targets, they require a relatively large dose to 
accumulate enough in the DV to reverse CQ-resistance.  In order to make use of an RA to 
restore the activity of CQ, it is necessary to find a way to target the RA to the site of 
action in malaria infections. 
 
Reversed-Chloroquines 
A solution was proposed to link the reversal agent covalently to a CQ-like moiety, 
forming a hybrid molecule, in this case a ‘Reversed-CQ’, that has a dual mode of action 
(Figure 1.11).63  The concept was that the CQ-like moiety can act as an antimalarial, 
while the reversal agent-like moiety can circumvent the mechanism of resistance; the 
covalent linkage between these two moieties ensures that they are both present in the DV 
at the same time.  It was hoped that a much smaller dose would be needed against CQ- 
resistant strains than when they are administered separately, minimizing the toxic effects 
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to the host.63  
To test the Reversed-CQ-concept, PL01 was synthesized by Steven Burgess.63  
PL01 is constructed to include an imipramine-like moiety (the RA) and a CQ-like moiety.  
Imipramine is a known reversal agent and fits the Bhattacharjee pharmacophore.62,64  The 
CQ methyl at the side chain C1 chiral center has been shown to be non-essential for 
antimalarial activity,65  and thus has not been included in the CQ-like moiety, leading to 
an achiral molecule.   
The antimalarial effectiveness of PL01 was evaluated by in vitro drug 
susceptibility assays against P. falciparum parasites.  The assays were conducted using 
D6 (a CQ-sensitive strain) and Dd2 (a CQ-resistant strain) P. falciparum cell cultures.  
PL01 gave an IC50 that was slightly lower than for CQ against the CQ-sensitive strain, 
and nearly a 20-fold increase in activity for the CQ against the CQ-resistant strain, 
making this value nearly that of the IC50 against the CQ-sensitive strain.  This indicates 
that PL01 is active against the CQ resistance mechanism present in the Dd2 CQ-resistant 
strain.  The reduced IC50 against CQ-sensitive strain relative to that of CQ may suggest 
Figure 1.11:  Reversed Chloroquine PL01 
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low-level resistance in the D6 CQ-sensitive strain, or may be a reflection of a fitness level 
difference between the strains.66  
 The antimalarial effectiveness of PL01 was also evaluated in an in vivo study in 
mice.  This study demonstrated that 64 mg/kg/day for 4 days suppressed over 99% of the 
P. chabaudi (a rodent malaria commonly used as a model organism).67  Poor 
bioavailability of PL01 was expected because of the drug’s lipophilic nature as estimated 
by clogP (the calculated log of the partition coefficient between n-octanol and water).  
The clogP of PL01 is 8.9, which is much higher than the 5.1 clogP of CQ.63  Lipinski’s 
Rule of Fives, a set of rules to estimate the solubility and permeability of investigational 
compounds, indicates that a logP of less than five is favored for a compound to be orally 
active.68  However, the mouse result demonstrates that PL01 has some oral 
bioavailability, and also has in vivo antimalarial activity.   
The binding constant of PL01 to the heme was evaluated by UV-vis titration.63  It 
was found that the Reversed-CQ-heme2 binding constant at pH 5.7 was about the same as 
for CQ-heme2 at the same pH, confirming 
that the modifications to the CQ-like 
moiety and the addition of reversal agent-
like moiety do not interfere with the 
binding of heme. 
PL02 (Figure 1.12) was designed 
on the same concept of linking a CQ-like 
molecule to an RA-like molecule.  Figure 1.12:  Reversed CQ Molecules Synthesized by Steven Burgess 
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However instead of using a known reversal agent, diphenylmethylpiperazine was chosen 
such that it possesses the essentials of the RA pharmacophore as defined by the 
Bhattacharjee study62  but without its “tricyclic antidepressant” structure.  In in vitro drug 
susceptibility assays against P. falciparum, PL02 gave a low IC50 against both CQ-
sensitive D6 and CQ-resistant Dd2.  In fact, the P. falciparum IC50 values were slightly 
lowered (improved) over the results for PL01.  Heme binding studies revealed nearly the 
same association constant as for PL01.  
 
PL74:  A Molecule of Interest 
PL74 (Figure 1.13 for amine-linkage target structure) was originally synthesized 
by Steven Burgess to be a PL02 analog without antimalarial activity, in order to test the 
RA activity.69  In a structure activity relationship (SAR) study of aminoquinolines, Egan 
concluded that the quinoline ring forms a complex with heme largely based on pi-pi 
interaction.54  Egan also concluded that the 7-chloro substituent on the quinoline ring is 
the minimum critical feature for 
β-hematin inhibition.54  In the 
change from PL02 to PL74 both 
the chlorine and half of the 
quinoline were removed.  It was 
postulated that this modification 
should abolish β-hematin 
inhibition and diminish the pi-pi 
Figure 1.13: Amine-Linkage Structure for PL74 
Proposed by Steven Burgess 
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interaction with heme.  
However, in vitro drug susceptibility assays were performed for PL74 against two 
cell cultures:  D6 (a CQ-sensitive culture) and Dd2 (a CQ- resistant culture).  It was 
found that the compound had an
 
IC50 for D6 (CQ-sensitive) of 185 nM and an IC50 for 
Dd2 (CQ-resistant) of 169 nM.69 These results are modest in comparison with the 
prototype Reversed-CQ but far better than anticipated (Figure 1.14, Table 1.1).   
Optical spectroscopic studies were carried out to determine equilibrium binding 
and β-hematin inhibition.70 For equilibrium binding, addition of the CQ and the PL 
compound showed a clear perturbation of the heme dimer absorption spectrum upon 
binding.  The 2:1 Affinity Model, in which the heme dimer bonds to one drug molecule 
(previously reported by Jane Kelly), can be used to determine the association constant 
(Ka) from the dose-response curve.71 The Ka for PL74 was determined to be 5,000, a 
five-fold reduction from the Ka of CQ.  Again, the value of Ka is small in comparison to 
CQ, PL01, and PL02--but still indicates that PL74 can associate with the heme dimer.  
For the β-hematin inhibition assay a solution of heme, Tween 20, and sodium 
acetate buffer (pH 4.8) was used to mimic the digestive vacuole environment.70  After 24 
hours incubation of this solution, there was a complete loss of absorbance in the Soret 
range, indicating the absence of measurable quantities of free heme.  On repeat with the 
addition of active PL compounds, the Soret band absorbance was preserved, indicating 
the presence of free heme, thus indicating the inhibition of β-hematin formation.  The 
inflection point of the sigmoidal dose-response curves indicates the IC50 of β-hematin 
formation.  The IC50 for PL74 was found to be 290 µM, a value more than 10x the IC50 
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for CQ, but still far greater than expected. See Table 1.1 for comparison of the β-hematin 
inhibition IC50 values for CQ, PL01, PL02, and PL74.  
  
Table 1.1:  In vitro Drug Susceptibility, Binding, and β-Hematin Inhibition Assay 
Results 
 In vitro Drug Susceptibility Assay UV Titration Studies 
 
IC50 (nM) D6 
 (CQ-sensitive) 
IC50 (nM) Dd2 
(CQ-resistant) 
Association 
Constant (Ka) 
IC50 (µM) 
β-Hematin 
Inhibition 
CQ 6.9 102 249,000 24 
PL01 2.9 5.3 110,000 9.0 
PL02 1.0 3.6 300,000 2.5 
PL74 185 169 50,000 290 
Figure 1.14:  Structures of CQ and Selected PL Compounds 
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The unexpected activity of PL74 was intriguing and warranted further 
investigation.  This dissertation is a record of the investigation.  Through these studies it 
was found that PL74 does in fact have some unique features and possibly a mode of 
antimalarial action different from the Reversed-CQ molecules.  As shown in the 
following chapters, both the structure of the molecule and its proposed mechanism of 
action needed revision. 
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Chapter 2 
 
 
 
The Structure of PL74 
 
 
 
PL74 and its proposed amine-linkage structure (Figure 2.1) were a paradox in 
some ways.  Not only did PL74 have stronger antimalarial activity than expected from 
the proposed amine-linkage structure, but its solubility and reactivity were also 
perplexing.  PL74 was not soluble in water above pH 5.5.  Attempts at syntheses via 
routes similar to those used for the RCQs were rarely successful.  These observations led 
me to propose a re-evaluation of the structure and propose an alternative pyridinium salt 
structure (Figure 2.1).  
The proton NMR peak assignments of the 1D spectrum acquired in methanol-d4 
originally made for the amine-linkage structure of PL74 are shown in Figure 2.2, 
Spectrum A.  These assignments were 
made based on consideration of 
analogous peak assignments for the RCQ 
molecules.  The amine-linkage structure 
is consistent with the chemical shifts, 
integral values, and signal splitting seen 
in the spectrum.   However, a careful 
examination of the proton NMR spectra 
in both methanol-d4 and DMSO-d6 gives 
Figure 2.1:  Proposed Structures for PL74 
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an indication that PL74 might be a pyridinium salt; the NOESY spectrum in methanol-d4 
gives the conclusive evidence.  For further assurance of the pyridinium structural 
determination, the PL74 spectra were evaluated in contrast to the analog PL343 spectra; 
PL343 is not a pyridinium salt but has an amine linkage.  My interpretation of the 1D and 
2D 1H NMR spectra of PL74 is as follows. 
 In the 1H NMR spectrum acquired in methanol-d4 (Figure 2.2, Spectrum A), five 
peaks appear in the aromatic region.  The AA'BB' spin system of the pyridine ring 
protons give rise to signals at 8.03 and 6.79 ppm.  Due to the electronegativity of the 
nitrogen, the two protons closest to the aromatic nitrogen are the most deshielded of the 
aromatic protons, and so give rise to the peak at 8.03 ppm.  The shielding from the 
electron density donated by the amine substituent shifts the second doublet upfield to 
6.79 ppm.  The 10 phenyl protons give rise to three signals at 7.41, 7.25, and 7.16 ppm, 
which integrate to 4H, 4H, and 2H, respectively, relative to the 2H integration of the 
pyridine doublet at 8.03 ppm.  There are also five peaks that appear in the aliphatic region 
in this spectrum.  The methine proton signal is a singlet at 4.20 ppm and has a relative 
integral value of 1H.  The ethyl linker chain gives rise to two triplets at 4.15 ppm and 
2.74 ppm, both with relative integration of 2H.  The eight piperazine ring protons are 
averaged by the chair-flipping of the ring and result in broad signals at 2.53 and 2.38 
ppm.  The methylene next to the piperazine nitrogen has a micro-environment most like 
the piperazine and so is assigned to the upfield triplet peak at 2.74 ppm.  The amine 
protons are not seen in methanol-d6 because they are exchanged with deuterium from the 
solvent.  The one indication in this spectrum that PL74 is, in fact, the pyridinium salt is 
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Figure 2.2:  Proton NMR Spectra of PL74 
Spectrum A:  1-d spectrum in methanol-d4; Spectrum B: 1-d spectrum in DMSO-d6 
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the methylene peak’s chemical shift, downfield to 4.15 ppm, suggesting that the protons 
are strongly deshielded; the position next to the aromatic quaternary nitrogen would be 
expected to lead to a strong deshielding effect, while the amine of the amine-linkage 
structure would not. 
There are two indications of the pyridinium salt structure seen in the DMSO-d6 1H 
proton spectrum (Figure 2.2: Spectrum B).  The amine protons, which would not 
exchange with the solvent, give rise to a signal at 8.10 ppm.  This amine peak overlaps 
with the downfield pyridinium peak, but the two peaks together have the relative 
integration of 4H; the 2H increase to the integral value indicates that the amine is a 
primary amine, as in the pyridinium salt structure, instead of the secondary amine, as in 
the amine-linkage structure.  In addition, when the amine proton signal appears in the 
spectrum, its nuclear spin will cause additional splitting on the vicinal protons; in the 
proposed structure, a splitting of the triplet to a doublet of triplets from this additional 
coupling would be seen.  The absence of the additional splitting on the peak at 4.15 ppm 
(peak c in Figure 2.2B) is a strong indication against the initially proposed structure.    
A nuclear Overhauser effect spectroscopy (NOESY) experiment measures the 
transfer of energy through space between protons that are within about 5 Å of each other; 
the closer the protons are in space the stronger the effect will be.  In the 2D NOESY 
spectrum (Figure 2.3) a cross peak, indicating energy transfer, correlates the methylene 
peak at 4.15 ppm to the pyridine peak at 8.03 ppm (indicated by the purple arrow in 
Figure 2.3).  There is no cross peak from the methylene peak at 4.15 ppm to the pyridine 
peak at 6.79 ppm, indicating that these peaks are further apart (region marked by purple 
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box in Figure 2.3).  This clearly indicates that the pyridinium structure is the molecule 
actually synthesized by Burgess.  
In the spectra of PL343 (Figures 2.4 and 2.5), the five expected observations are 
seen for a molecule with an amine linkage between the 4-aminopyridine and the 
headgroup.  In the 1H-spectrum recorded in methanol-d4, Figure 2.4A, the triplet arising 
from the methylene near the amine is shifted further upfield to 3.51 ppm, midway 
between the piperazine protons at 2.50-2.62 ppm and the methine protons at 4.27 ppm.  
In the 1H-spectrum in DMSO-d6 (Figure 2.4: Spectrum B), the amine proton peak at 8.51 
Figure 2.3:  NOESY Spectrum of PL74 in Methanol-d4  
(Purple arrow indicates cross peak between aromatic peak a and methylene peak c.  Purple box around 
region where a cross peak between peak b and methylene peak c would occur.) 
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Figure 2.4:  Proton NMR Spectra of PL343 
Spectrum A:  1-d NMR spectrum in methanol-d4; Spectrum B: 1-d NMR spectrum in DMSO-d6    
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ppm has a relative integration of only 1H.  In the DMSO-d6 1H-spectrum, there is 
additional splitting from the coupling between the amine proton peak at 8.51 ppm and the 
adjacent methylene peak at 3.42 ppm. 
Finally, in the NOESY spectrum acquired in DMSO-d6 (Figure 2.5) there are 
through-space correlations from the methylene at 3.51 ppm (peak d) to the amine peak at 
8.51 ppm and from the methylene peak at 3.51 ppm (peak d) to the pyridine peak at 6.98 
ppm (peak b).  These five features clearly indicate that PL343 is an analog with an 
amine-linkage and, when contrasted with the PL74 spectral features, these observations 
confirm that PL74 does not have the previously reported amine-linkage. 
 
Figure 2.5:  NOESY Spectrum of PL343 in DMSO-d6 
(Right arrow indicates cross peak from amine proton peak to methylene peak d.  Left arrow indicates 
cross peak from aromatic peak b to methylene peak d.) 
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Based on the evidence just presented, the molecule named PL74 has been 
determined to have a pyridinium salt structure.  The “yet-to-be-synthesized” amine-
linkage structure will be named PL388 from here forward.   
Once the structure of PL74 was determined to be a pyridinium salt, the spectra for 
each analog I had synthesized were examined to determine which was a pyridinium salt.  
It was found that every analog that was synthesized using a 4-aminopyridine starting 
material resulted in a pyridinium salt; while each analog synthesized not using a 4-
aminopyridine had the expected amine linkage. 
 
 
 
 
 
36 
 
Chapter 3 
 
Structure Activity Relationship: Part 1 
 
An SAR study was initiated for the purpose of optimizing in vitro antimalarial 
activity and to gain insights into the mechanism of action of PL74.  The quaternary 
ammonium moiety is a unique feature among the compounds that have been made in the 
Peyton laboratory to date. (See Figure 1.12 for examples of Peyton Lab Compounds)  
The presence of a quaternary ammonium cation and its impact in the conjugated 
aminopyridine system is therefore of special interest.  Analogs with modifications to the 
pyridine ring and the ethyl linker chain attached to the cationic center were prepared for 
study and tested for in vitro antimalarial activity.  In addition, analogs were prepared and 
tested to investigate the role of RA-like moiety of this compound.   
The general synthesis pathway (Figure 3.1) used for the pyridinium compounds 
was the route reported by Steven Burgess.69  In this synthesis, chlorodiphenylmethane is 
combined with 1-(2-hydroxyethyl)piperazine to give PL72.  The alcohol is treated with 
thionyl chloride, then treated with the appropriate 4-aminopyridine in ethanol to yield the 
PL74 analog.  This synthesis was found to be a simple and reliable method.   However, 
attempts to increase the yield of the final step by the addition of base gave the opposite 
result; several bases were tried, and each attempt resulted in drastically diminished yield.  
It was found that no base, including using only 1 eq of the amine (as opposed to the 4 eq 
used by Burgess), led to improved yields for the addition of 4-aminopyridine.   
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Another synthetic pathway was explored, as shown in Figure 3.2.  In this 
synthesis, the appropriate amine was treated with chloroacetyl chloride, resulting in an 
acyl pyridinium.  The isolated acyl pyridinium was then treated with 
diphenylmethylpiperazine, followed by reduction with LiAlH4.  The acyl pyridinium was 
very easy to isolate but the yields were 20%, at best.  The reduction in the final step was 
very difficult and resulted in yields below 5%.  Several of the analogs were made by this 
route but it is not the recommended pathway because of the low yields. 
  
Figure 3.1: Synthesis Pathway for PL74 and Its Analogs 
Figure 3.2:  Alternative Synthesis Pathway for PL74 Analogs 
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The in vitro antimalarial activities of the purified products were measured through 
drug susceptibility assays against P. falciparum parasites in red blood cell culture.63  The 
results shown are measurements carried out in triplicate, and are interpreted as active or 
inactive; compounds with an IC50 > 2500 nM are considered inactive.  Repeat 
measurements (in triplicate) were made only for PL74. The IC50 reported by Burgess was 
IC50 of 185 nM against the CQ-sensitive P. falciparum D6 strain and 169 nM against the 
CQ-resistant P. falciparum Dd2 strain.  On a repeat test, PL74 had higher IC50 values of 
385 nM against D6 (CQ-sensitive strain) and 245 nM against Dd2 (CQ-resistant strain).  
This illustrates that there is some variability in the testing; thus smaller fluctuations in 
IC50 (<3 fold) are only considered to be significant if a discernable trend across several 
compounds was found and not considered significant if the fluctuation involved only a 
single compound.  Also, the higher, more recent results are the ones that will be used for 
comparison since the IC50 measurements were made at or near the time of testing for the 
other analogs.      
A set of four compounds, PL324, PL325, PL327, and PL328, were made that 
include substituents on the pyridine ring (Figure 3.3).  The methyl and bromine 
substituents were chosen because they are similar in size (van der Waal volumes of 22.7 
Å3 and 23.9 Å3, respectively) and have the opposite electronic effects, methyl donating 
and bromine withdrawing electron density.  Analog PL327 was synthesized with a 
bromine substituent at the ring position alpha to the quaternary ammonium nitrogen but 
was converted to the methoxy during workup with 100% conversion. 
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The Hammett sigma constant (σ) indicates the electronic effect of a substituent on 
the acid dissociation of benzoic acid; these values can be used as an estimate in other 
aromatic systems.  Negative sigma values indicate that the substituent is donating 
electrons into the system, and positive values indicate the withdrawal of electrons from 
the system.  The Hammett constant is dependent on the position on the  
 ring, relative to the carboxy moiety.  In the meta-position, the substituent effect is 
inductive; in the para-position, there is both an inductive and resonance effect.  The 
resonance effect can be estimated by the difference of the para- and meta-values.  
Literature σmeta, σpara  and the difference for the bromo, methyl, and methoxy substituents 
are given in Table 3.1.    
The substituent effect in the ortho-
position is more complicated in that it 
includes a steric effect in addition to the 
inductive and resonance effects, and σortho is 
generally not used.  The closer the substituent is to the reaction center, the more enhanced 
the effect will be; when the reaction center is in the ring, the substituent effect is 
enhanced.  The Hammett Equation cannot be rigorously applied to determine specific 
effects in the complex pyridinium system.  (It is also not accurate to apply the 
nomenclature positions ortho, meta and para for the relationship to the quaternary 
ammonium cation in the ring, however to simplify this discussion and stay in step with 
the Hammett constants, ortho-to-the-cation and meta-to-the-cation will be used.)  It can 
be said that at the position meta-to-the-cation, the methyl will be electron donating and 
Table 3.1  The Hammett Substituent Constants 
(σ) Based on Ionization of Benzoic Acid 
Substituent σmeta σpara σpara-σmeta 
Bromo 0.391 0.232 -0.159 
Methyl -0.069 -0.107 -0.038 
Methoxy 0.115 -0.268 -0.383 
Amino -0.016 -0.66 -0.64 
Methylamino --- -0.84 --- 
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the bromo will be electron withdrawing.  Also, it can be said that at the position ortho-to-
the-cation it is not clear if the methyl and methoxy groups are electron donating or 
withdrawing because of the steric contribution, but their effect may have a strong impact 
on the reaction center because of their close proximity to the cation.  
The analogs, PL324, PL325, PL327, and PL328, all show in vitro antimalarial 
activity for both the CQ-sensitive and CQ-resistant strains; the IC50 values are shown in 
Table 3.2.   From these results it can be seen that substituents on the ring are generally 
tolerated.  With the addition of electron-donating methyl substituents on PL324 and 
PL325 and the electron-withdrawing bromo substituent on PL328, there was little change 
from   the antimalarial activity of PL74.  
With the addition of a methoxy group on 
PL327, there is a significant drop in 
antimalarial activity .    
The general tolerance for the 
Table 3.2: IC50 Values of Analogs with Pyridine 
Ring Substituents  (PL74 IC50 included for 
comparison) 
 
IC50 (nM) D6 
(CQ-Sensitive) 
IC50 (nM) Dd2 
(CQ-Resistant) 
PL74 385  245  
PL324 344  229  
PL325 539  378  
PL327 1529 836  
PL328 433 300 
Figure 3.3: Analogs with Pyridine Ring Substituents  
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addition of substituents to the pyridine ring suggests that at the site of action there is 
space to accommodate the substituents as the compound performs its mechanism of 
antimalarial action.  This advantageous characteristic allows for future SAR 
investigations and possibly increasing the functionality of this compound.   
 The methoxy substituent was not tolerated in the position ortho-to-the-cation, 
while the methyl was tolerated.  The electron contribution of the methoxy is unclear but it 
certainly has a much larger capacity for electron donation through resonance than the 
methyl substituent.  If the steric constraints at this location allow for resonance, then it 
may be that methoxy has a strong electron-donating effect and the resulting decreased  
cationic charge is disfavored.   However, if the steric constraints hinder resonance, then 
the electron-withdrawing inductive effect of the oxygen in close proximity may be the 
result of increased cationic charge being disfavored. 
Analogs PL342, PL330, PL165 and PL240 show further examples of analogs that 
may perturb the electronic nature of the quaternary aromatic nitrogen (Figure 3.4).  
Analog PL342 has a methylamine substituent instead of a primary amine at a position 
para-to-the-cation.  The methylamine has a greater electron-donating ability than the 
amine substituent, indicated by the larger negative sigma values (Table 3.1).  A slight 
increase in antimalarial activity is seen for PL342 in comparison to PL74, indicated by 
the IC50 that is lower than the IC50 of PL74.  The small increase is insignificant by the 
evaluation standard set forth in this dissertation.  However, the increase is still enough to 
prompt the design of analogs that include stronger electron-donating substituents at this  
location for future SAR studies.  
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     The second aromatic nitrogen in 
PL330 serves as an electron sink by 
inductive effects, strongly drawing electron 
density away from the quaternary nitrogen.   
The carbonyl group of PL165 also serves as 
an even stronger electron-withdrawing 
influence on the quaternary ammonium.  The more distant carbonyl in PL240 has only a 
minor inductive effect on the quaternary ammonium.  PL240, PL330 and PL165 all show 
a drop in antimalarial activity; the magnitudes of the loss of activity increases with the 
strength of electron-withdrawing modification (Table 3.3).  Strong electron-withdrawing 
effects reduce the antimalarial activity.  The increase of the cationic charge seems to be 
disfavored. 
    Table 3.3:  IC50 Values for PL330, PL342, 
PL240, and PL165  (PL74 IC50 included for 
comparison) 
 
IC50 (nM) D6 
(CQ-sensitive) 
IC50 (nM) Dd2 
(CQ-resistant) 
PL74  385  245  
PL342  266  206  
PL330 1880          1385  
PL165       >2500        >2500  
PL240  647  984  
Figure 3.4: PL74 Analogs 
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In the analogs PL238, PL236, PL232 (Figure 3.5), the functionality of the RA-like 
moiety is incrementally subtracted.  This series was planned to help determine which 
parts of the RA-like moiety are essential for antimalarial activity and/or reversal 
activity for CQ-resistant strains.  It was envisioned that a loss of antimalarial activity 
against the resistant strain might be seen earlier in the series than the loss of activity 
against sensitive strain.  Instead, a most surprising result was seen: there is total loss of 
antimalarial activity with the removal of even one phenyl ring (Table 3.4).  
However, with the removal of a nitrogen 
from the piperazine ring, the loss of a 
phenyl ring is tolerated as shown by the 
activity of PL297, possibly indicating 
that it is the exposure of the nitrogen 
that is the underlying cause for activity 
loss.  
Table 3.4:  IC50 Values for PL238, PL236, 
and PL232 (IC50 of PL74 included for 
comparison) 
 
IC50 (nM) D6 
(CQ-sensitive) 
IC50 (nM) 7G8 
(CQ-resistant) 
PL74     385 345(Dd2) 
PL238 >2500 >2500 
PL236 >2500 >2500 
PL232 >2500 >2500 
PL297    654 371(7G8)/ 684(Dd2) 
Figure 3.5:  Analogs with RA Modifications 
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The sensitivity to RA modifications is a very different than what is seen for the 
Reversed-CQ SAR.   For quinoline analogs, PL06 and DM1020, the change from two 
phenyl rings to one showed no loss of antimalarial activity.69  PL110, PL91 and PL228, 
reveals a series of further RA modifications that led to significant increases in 
antimalarial activity (see Figure 3.6).73  The intolerance for modification to the RA 
moiety implies that the entirety of PL74 is the antimalarial pharmacophore.  In this, PL74 
analogs demonstrate a drastic departure from Reversed-CQ-like behavior, possibly 
indicating a mode of action other than the inhibition of hemozoin. 
 
Figure 3.6: Reversed-CQ Compounds with RA Modifications 
(Compounds synthesized by Steven Burgess and Bornface Gunsaru with PL74 and PL238 included 
for comparison) 
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The inactivity of PL238, while differing from PL74 by the loss of a single phenyl, 
suggests the possibility of an antimalarial different from the Reversed-CQs, and so 
possibly an enzyme binding site.  The regain of activity with the change to a piperidine 
ring in PL297 may be showing the lipophilicity of a binding site.  These indications of a 
possible new mechanism of antimalarial activity warrants further investigation. 
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Chapter 4 
 
 
 
Structure Activity Relationship: Part 2 
 
 
 
In the course of the SAR study, several analogs synthesized were made with the 
pyridine ring attached to the head group via an amine linkage.  It was surprising to find 
that there is also antimalarial activity among these compounds.  Eight compounds are 
presented.  Although the eight compounds comprise a sparse and somewhat disjointed 
SAR study, they raise some interesting questions regarding the activity of the amine-
linkage compounds.   
The compounds were purified and the in vitro antimalarial activities were 
measured in triplicate through drug susceptibility assays against P. falciparum parasites 
in red blood cell culture.63  As before, the results are interpreted as active or inactive; 
compounds with an IC50 > 2500 nM are considered inactive.   
PL167 is the most active antimalarial compound among this group.  PL167 is 
based on the 3-aminopyridine and was synthesized via the alternate synthetic route for 
the pyridinium salts; in this case the amine substituent acts as the nucleophile leading to 
the amine linkage, instead of the aromatic nitrogen acting as the nucleophile leading to 
the pyridinium salt as with 4-aminopyridine.  The synthesis pathway is shown in Figure 
4.1.  PL169 was also made in this same reaction sequence but starting with the 2-
aminopyridine.  The syntheses of the remaining analogs are quite varied and given in 
Chapter 7. 
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Upon in vitro testing, PL167 showed good antimalarial activity, with an IC50 of 
450 nM against D6 (a CQ-sensitive strain) and 173 nM against Dd2 (a CQ-resistant 
strain).  While PL167, based on 3-aminopyridine, is an active compound, PL169, based 
on the 2-aminopyridine, is inactive (Figure 4.2, Table 4.1).  This is not the expected result 
based on the quinoline compounds.  In an SAR study of aminoquinolines, Egan found 
that 2-aminoquinoline and 4-aminoquinoline derivatives which are conjugated had strong 
antimalarial activity while the 3-aminoquinoline did not.54  Egan also found that the 4-
aminoquinoline derivatives had better antimalarial activity than the 2-aminoquinoline 
derivatives.54  The strong antimalarial activity of PL169, the 3-aminopyridine derivative, 
is uncharacteristic of the aminoquinoline antimalarial activity suggested by Egan. 
PL360 is an analog of particular interest in that it was designed as a pyridine 
mimic of CQ to address the question of whether or not these pyridine-based compounds 
are recognized by the CQ resistance mechanism (Figure 4.2).  It was hypothesized that if  
  
Figure 4.1: Synthesis Pathway for PL167 
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Table 4.1:  IC50 Values of Analogs of Analogs with 
Amine Linkage (IC50 of PL74 included for comparison) 
 
IC50 (nM) D6 
(CQ-Sensitive) 
IC50 (nM) Dd2 
(CQ-Resistant) 
PL74   385    245  
PL76 >2500  >2500  
PL167     450      173  
PL169 >2500  >2500  
PL215 >2500    1267  
PL329 >2500  >2500  
PL343 >2500    1957  
PL350     851    2030 
PL360 >2500  >2500 (7G8) 
Figure 4.2:  Amine-Linkage Analogs 
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this CQ mimic is active against the CQ-sensitive strain and not against the CQ-resistant  
strain, then it may be concluded that the activity of the pyridine moiety is similar to the 
quinoline moiety.  Antimalarial testing resulted in an IC50 >2500 nM for both D6 (a CQ-
sensitive strain) and 7G8 (a CQ-resistant strain).  If there is CQ-like antimalarial activity 
that arises from the 4-aminopyridine, it should be seen in this analog.  The inactivity of 
PL360 suggests that the aminopyridine moiety does not completely encompass the 
antimalarial activity of the amine-linkage molecules; more than the aminopyridine seems 
necessary for activity.   
PL350, a 4-aminopyridine-based compound, is the closest analog to the amine-
linkage structure first proposed for PL74 (and now referred to as PL388); PL350 differs 
by the addition of a 3-hydroxy substituent (Figure 4.2).  Upon in vitro testing PL350 
showed antimalarial activity against the sensitive strain, with an IC50 of 851 nM against 
D6 (a CQ-sensitive strain) and 2030 nM against Dd2 (a CQ-resistant strain), making 
PL350 the only molecule in this study to show the significant reduction of reversal agent 
activity with retention of antimalarial activity.  A general trend that is seen among the 
pyridine and quinoline compounds is that for a given compound the IC50 value is lower 
against the CQ-resistant strain than against the CQ-sensitive strain.  The trend can be 
seen in the compounds in this study (Table 4.1).  The trend may be a reflection of the 
fitness level of the strains.  The adaptations that endow a strain with drug resistance seem 
to be costly in terms of overall fitness as shown by competitive growth measurements.66  
With strain fitness in mind, the IC50 results for PL350 being 2.5 times higher against the 
resistant strain than against the sensitive strain is a significant result.  It is interesting that 
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in this molecule the reversal agent activity seems to be uncoupled from the antimalarial 
activity and yet no modifications have been made to what is perceived as the reversal 
agent portion of the molecule.  This may be an important design lead for investigation of 
the essential moiety for the reversal of CQ resistance in further SAR studies of the amine-
linkage compounds.   
PL343 is arranged like PL350 but has a 3-nitro group instead of a 3-hydroxy 
group; PL343 has an IC50 of >2500 nM for D6 (a CQ-sensitive strain) and 1957 nM for 
Dd2 (a CQ-resistant strain). It is interesting that the change from the 3-hydroxy to the 3-
nitro substituent changes the CQ-sensitive antimalarial activity from 851 nM to inactive, 
while the CQ-resistant antimalarial activity is the same for both (Table 4.2).  
PL215 and PL329 have a carbon moiety inserted between the secondary amine 
and the pyridine ring (Figure 4.2).  For PL329, the carbon moiety is a carbonyl and the 
compound is inactive against both strains.  For PL215, the carbon moiety is a methyl 
group and the compound is inactive against D6 (a CQ-sensitive strain) but retains slight 
activity against Dd2 (a CQ-resistant strain).  In addition, PL76 is based on a phenyl 
moiety instead of a pyridine moiety and is found to be inactive for both the CQ-sensitive 
and CQ-resistant strains, suggesting that the aromatic nitrogen is an essential moiety for 
in vitro antimalarial activity.  Certainly, a more thorough SAR study is needed to 
elucidate the pattern of antimalarial activity among the amine-linkage molecules.    
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Chapter 5 
 
Quaternary Ammonium Compounds 
 
Because the range among antimalarial drugs is limited in terms of number of 
unique targets, and because cross-resistance to all deployed drugs continues to emerge, it 
is urgent that new antimalarials continue to be developed with some priority given to 
molecules that have modes of action different from those currently in use.  If PL74 has a 
unique mode of antimalarial action, as suggested in the SAR study, then it is important 
that we explore this compound further to gain understanding of its antimalarial mode of 
action and its suitability as a lead compound for drug development.   
A survey of literature reveals rich veins of research into applications for 
quaternary ammonium compounds.  The work of Dr. Henri Vial and associates at 
University of Montpellier II shows a relentless pursuit of understanding of the biogenesis 
of phospholipids in P. falciparum and the rational design of novel choline inhibitors as 
antimalarials (References included in discussion).  A careful look at the work to elucidate 
the mode of action of their lead compound gives insight into a possible mechanism of 
activity and a possible direction for future work to optimize PL74 into a drug.  
 
The Antimalarial Action of Albitiazolium 
The P. falciparum blood stage proliferation process demands the biosynthesis of 
large amounts of phospholipids for the construction of membranes.  From the time of the 
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parasite’s invasion of the red blood cell (RBC) until the rupture of the cell 48 hours later, 
the phospholipid content of the cell increases 500-600 fold.74-76  Because the increased 
amount of phospholipids is essential for the maturation and replication of the parasite, the 
phospholipid synthesis process is an attractive target to consider for drug development.77  
 The biosynthesis of phospholipids in P. falciparum is well known.78-81 The 
majority of the phospholipids are phosphatidylcholine (40-50%) and 
phosphatidylethanolamine (35-45%).82  An overview of these synthetic pathways is 
shown in Figure 5.1.  The production of phosphatidylcholine begins with the uptake of 
host choline into the infected RBC.  The uptake occurs mainly via a saturatable process, 
and occurs through the erythrocyte choline transporter.  One quarter of the choline enters 
via the New Permeation Pathway (NPP) which is a parasite-induced channel in the 
membrane of the erythrocyte.83-87  The choline is further transported through the parasite 
membranes through a dedicated choline transporter.88  The capacity of the transporters of 
choline through the erythrocyte membrane is much lower than the capacity of the 
transporters through the parasite membranes, making the trans-erythrocyte membrane 
transport the probable rate-limiting step.88  Choline is transformed to phosphocholine in 
the cytosol of the parasite, then to cytidine diphosphate choline, and finally to 
phosphatidylcholine via choline kinase, CTP-phosphocholine cytidylyltransferase, and 
choline/ethanolamine phosphotransferase.     
Phosphatidylethanolamine is made from ethanolamine.  Ethanolamine diffuses 
from the plasma through both the erythrocyte and parasite membranes into the cytosol, or 
is made by decarboxylation of serine.78-81  The serine is either imported or captured from 
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hemoglobin degradation products.  In the same manner as choline, ethanolamine is 
transformed to phosphoethanolamine, then to cytidine diphosphate ethanolamine, and 
finally to phosphatidylethanolamine via ethanolamine kinase, CTP-phosphoethanolamine 
cytidylytransferanse, and choline/ethanolamine phosphotransferase.  In addition, 
phosphoethanolamine can be converted to phosphocholine by methylation via the 
phosphoethanolamine methyltransferase.  In the same way, phosphatidylethanolamine 
can be converted to phosphotidylcholine (Figure 5.1). 
 
Figure 5.1:  Biosynthetic Pathways of Phospholipids 
Remake of graphic from ChemMedChem 2012, 7, 22-31 
Compartments: E: erythrocyte, CS: cytosome, PV: parasitophorous vacuole, DV: digestive vacuole 
Transporters : NPP: new permeation pathway; OCT: organic-cation transporter; eChoT:erythtocyte 
choline transporter 
Enzymes: PfCK: choline kinase; PfCCT: CTP-phosphocholine cytidylyltransferase; PfCEPT: 
choline/ethanolamine cytidylyltransferase; PfPMT: phosphoethanolamine methyltransferase; PLMT: 
phospholipid methyltransferace; SD: serine decarboxylase 
Substrates: Cho: choline; P-Cho: phosphocholine; CDP-Cho: cytidine diphosphate choline; PtdCho: 
phosphatidylcholine; P-Etn: phosphoethanolamine; CDP-Etn: cytidine diphosphate ethanolamine; 
PtdEtn: phosphatidylethanolamine; Hb: heme;  Ser: serine;  Etn: ethanolamine 
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The pathways from choline to phosphatidylcholine (Figure 5.1: shown in black) 
and from ethanolamine to phosphatidylethanolamine (Figure 5.1: shown in blue) are 
known as the Kennedy pathways, and are highly conserved in eukaryotes.  The pathway 
from serine to phosphoethanolamine via decarboxylation and then to phosphocholamine 
via methyltransferase has been identified in P. falciparum but is more plant-like in nature; 
this pathway is named the serine decarboxylation-phosphoethanolamine methylation 
(SDPM) pathway (Figure 5.1: shown in green).78-81 
The Vial group set out to identify choline analogs with antimalarial activity.  By 
the screening of ammonium salts for antimalarial activity, several such analogs were 
discovered. 89-91  By comparing and contrasting the active and inactive molecules, it was 
seen that the antimalarial activity was increased by the addition of a 10-to-12 carbon 
chain and by adding lipophilic bulk around the nitrogen, creating a head group between 
200 and 400 Å3.91  A selection of a few of the more active compounds found from their 
SAR studies are shown in Figure 5.2. 
 
Figure 5.2: Choline Analogs 
55 
 
The potential potencies of these compounds were revealed when bis-ammonium 
salts were formed by tethering a set of duplicate ammonium compounds together with a 
long carbon chain.  From compounds shown in Figure 5.3, it can be seen that changing 
the original mono-structure to a bis-structure can lead to a large improvement in 
antimalarial activity, shown by the decrease in IC50 values.90   
G25 and MS1 both showed good antimalarial activity in vitro as indicated by the 
IC50 values shown.90,91  In addition, both G25 and MS1 showed potent activity in vivo 
when administered intraperitoneally to P. vinckei-infected mice; their ED50 values were 
0.22 mg/kg and 1.6 mg/kg, respectively.  Further testing for compound G25 revealed its 
potency against P. falciparum in Aotus monkeys; a complete cure was achieved at a dose 
of 0.30 mg/kg.  In spite of the good results seen for both of these bis-quaternary 
compounds, they were found to have bioavailability problems on oral administration that 
was attributed to the low permeability of the gastero-intestinal barrier to the permanent 
cationic charges.90,91 
T3 was chosen as the Vial group’s lead molecule because it was envisioned that a 
neutral pro-drug could be designed that would improve the oral availability of the 
drug.90,91  The neutral pro-drug (Pro-T3) is transformed to the drug by the enzymatic 
action of an esterase.91   T3 and Pro-T3 have very good antimalarial activity in vitro 
against P. falciparum; the IC50 of T3 is 2.25 nM and the IC50 of Pro-T3 is 3.0 nM.91  In 
addition T3 showed good activity in vivo when administered intraperitoneally to P. 
vinckei-infected mice with an EC50 of 0.2 mg/kg, however it was shown to be ineffective 
when administered orally with an ED50 of 13 mg/kg.91  The in vivo activity of Pro-T3 
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Table 5.1: The Antimalarial Activity of Mono- and Bis-Quaternary Ammonium Compounds 
Mono-Compound in vitro IC50 (nM) Bis-Compound in vitro IC50 (nM) 
QA6 500 T4 90 
E26 420 G25 0.64 
MS23 1550 MS1 0.5 
T1 70 T3 2.25 
  Pro-T3 3.0 
Figure 5.3:  Mono- and Bis-Quaternary Ammonium Compounds 
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when administered intraperitoneally to P. vinckei-infected mice was nearly the same T3 
with an IC50 of 0.25 mg/kg; Pro-T3 was found to be more effective than T3 when 
administered orally with an EC50 of 5 mg/kg.91  The neutral pro-drug approach has been 
successful as shown by activity upon oral administration.  A Pro-T3 analog that could not 
be transformed to the thiazolium showed an in vitro IC50 < 10 µM, suggesting the 
transformation of Pro-T3 to the active form does occur in vivo.90   
Based on the dramatic increase in the antimalarial activity seen in the bis-
ammonium compounds, it was hypothesized based on the structures of the active analogs 
that there are two active anionic binding sites on the target protein.  The optimized chain 
length suggests the distant between the active sites.91  The SAR included alterations to 
the chain, and all alterations tried diminished the antimalarial activity.  The negative 
impact of polar functional groups added to the carbon chain suggested that the region 
between the active sites is hydrophobic.  The negative impact of aromatic rings that add 
rigidity to the chain suggests that the pathway between the binding regions is narrow or 
convoluted.91   
In the paper, “Transport and Pharmacodynamics of Albitiazolium, an 
Antimalarial Drug Candidate”, the Vial group reports the results of their exploration of 
the mode of action of albitiazolium (T3).  A detailed analysis of the inhibitory effect of 
albitiazolium on phosphocholine and phosphoethanolamine biosynthesis was performed 
for three distinct parasite development stages in the erythrocyte.  The measurements were 
made at the ring stage, which is the immature parasite stage from invasion to the 
formation of the parasitophorous vacuole; the trophozoite stage, which is a maturation 
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phase that includes heightened metabolism; and finally the schizont stage, in which the 
DNA replicates and is followed by rapid cell division.92  Because the need for 
phospholipids differs throughout the stages, it was expected that the potency of the drug 
would show a stage-specific pattern.  The drug concentration that inhibited 50% of the 
phosphocholine synthesis (PC50) was determined to be 2.8 µM for the ring stage, 26 µM 
for the trophozoite stage and 9.3 µM for the schizont stage.88 The drug concentration that 
inhibited 50% of the phosphoethanolamine synthesis (PE50) was greater than 1000 µM 
for all three developmental stages.88  Albitiazolium thus specifically inhibited 
phosphocholine synthesis, and had its most potent immediate effect against the immature 
parasite.  In addition, increased choline concentrations in the cell media showed an 
antagonistic effect on the antimalarial potency albitiazolium, indicating that not only does 
albitiazolium inhibit phosphocholine synthesis, but it is that inhibition that leads to its 
overall antimalarial affect.  On further in vitro testing, it was shown that even with short 
drug exposure times of 1 to 2 hours at any parasitic stage of development, the drug 
accumulated within the intracellular parasite and led to its collapse at the onset of the 
schizont stage.77,93  
Albitiazolium was shown to accumulate selectively in the infected RBCs.93  When 
erythrocytes were incubated at 37 oC in 30 µM albitiazolium media less than 0.01 
pmol/107 RBC·min-1 entered the uninfected RBC.  A 400-fold accumulation of drug 
inside the infected RBC was measured when the cell media concentration was at 100 
nM.88  The uptake of albitiazolium into the infected RBC proceeded linearly until 
saturation at 5 µM.88  The selective uptake into the infected RBC implicates the parasite-
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induced NPP. Furosemide is a known NPP inhibitor,84,94,95 and was shown to inhibit 
albitiazolium uptake.88  However, even at very high concentrations furosemide was only 
able to reduce the uptake by 85%.88  It appears that the majority of the albitiazolium 
enters the RBC via the NPP, but some uptake is via an unknown route that is not 
inhibited by furosemide.   
Albitiazolium is then transported from the RBC into the parasite, most likely via 
an organic cation transporter.89  The cross inhibition of choline on albitiazolium transport 
and of albitiazolium on choline transport was taken as evidence that they leave the RBC 
cytosol and enter the parasite by way of the same transporter.88  The capacity of NPP-
mediated transport of the albitiazolium from the plasma into the cytosol of the RBC is 
much smaller than the capacity of its transport from the cytosol of the RBC into the 
parasite.88  Because the second transporter in the series is larger, it seems reasonable to 
conclude that the majority of the drug accumulation is inside the parasite, not in the 
cytosol of the RBC.  Accumulation measurements on a choline analog that is closely 
related to albitiazolium was found to reside 77% inside the parasite and 23% in the 
cytosol of the RBC.88   
Albitiazolium interferes with choline phospholipid production in two ways, 
inhibiting both the transport of choline from host plasma to parasite cytosol, and 
inhibiting enzymatic transformations of choline to phosphatidylcholine.  Albitiazolium 
has been shown to inhibit the transport of choline with an IC50 of 19 µM in infected 
RBCs incubated in the presence of 15 µM choline.88  When this was repeated in the 
presence of furosemide, the NPP inhibitor, the IC50 for choline transport was 1.9 µM.88  
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This suggests that the drug is inhibiting the transport of choline through the erythrocytic 
choline transporter.  The parasitic biosynthesis pathway from choline to 
phosphatidylcholine involves three enzymes: choline kinase, CTP-phosphocholine 
cytidylyltransferase, and choline/ethanolamine cytidylyltransferase.  Albitiazolium 
inhibited each of these enzymes with IC50s of 1.5 nM, 2.5 nM, and 4.2 nM, respectively, 
when assessed on parasite extracts at optimal conditions for enzymatic catalysis. 
In addition, it may also be that a portion of this drug accumulates in the digestive 
vacuole of the parasite and inhibits the biocrystallization of hemozoin as has been 
determined for other bis-thiazolium compounds.96  The affinity for the binding with heme 
has been shown to both enhance the level of accumulation in the infected RBC and the 
antimalarial activity of the bis-thiazolium compounds, although this has not been thought 
to be the primary mode of action for this class of antimalarials.96 
 
 
The Anticancer Activity of bis-Quaternary Ammonium Compounds 
Neoplastic cancer is an area where bis-quaternary ammonium compounds are 
found to be useful.97  Cancer is often viewed as simply wild proliferation of a cell but a 
deeper look shows the basis of cancer is damage to genes that encode proteins used to 
send signals to the nucleus to initiate cell growth, mitosis, differentiation, and/or 
apoptosis.98  As a result of accentuated or diminished messages, cells begin to behave in 
abnormal ways, often resulting in malignant tumors. 
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The ras gene family encodes proteins that are involved in the signaling of cellular 
functions.  Oncogenic ras genes are found in 25% of human cancer and their mutations 
have been found to have impaired ability to terminate signaling, resulting in the 
upregulation of cell proliferation.99,100  Choline kinase (ChoK) is thought to be a part of 
this signaling pathway that controls the regulation of cell growth.97  ChoK catalyzes the 
transformation of choline phosphocholine (PCho) and elevated concentrations of PCho 
are found in cancer cells that have ras mutations.  Also, inhibition of ChoK with bis-
quaternary ammonium compounds has been shown to correlate with the inhibition of 
tumor cell proliferation.97   
 Joaquin Campos, Antonio Espinosa, and coworkers have performed a QSAR 
study based on the lead bis-quaternary ammonium compound of Hemicholinium-3 
(Figure 4) in hope of developing an effective antiproliferant drug.  Hemicholinium-3 is a 
known, potent ChoK inhibitor in vitro, but it is unsuitable for use as a drug because it 
causes respiratory paralysis.101  The SAR studies have led them to bis-aminopyridinium 
compounds with improved activity without the respiratory paralysis side-effect.  
Examples of their active compounds are shown in Figure 4.   
Campos and Espinosa have found that the quaternary nitrogen is essential to 
inhibitory activity and that an electron donating group at the position para-to-the-
quaternary-nitrogen on the pyridine ring enhances activity.  They have also found that the 
number and distribution of the cationic charges greatly influence their activity and 
toxicity. 
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 Molecular orbital calculations were used in an attempt to find trends that 
explained the changes in potency seen through the series.102  It was found that the ChoK 
inhibition tightly correlated with the energies of the HOMOs and LUMOs of the 
compounds; increases in the energy level of the frontier orbitals led to increased activity.  
The HOMO and LUMO energies levels increased as the electron-donating ability of the 
para substituent increased.  The authors stressed the need for a quantitative approach to 
 
 
Figure 5.4: Structure and Activity of Bis-Quaternary Compounds 
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the SAR because analogs that appeared to be very different may in fact be electronically 
similar, while those that appear similar may be very different.  Also, it was pointed out 
that a deeper understanding of the electronic nature of the inhibitor would lead to a better 
understanding of the possible interaction between the enzyme and the inhibitor.  In the 
case of ChoK and the 4-aminopyridinium compounds it was rationalized that the high 
energy level of the LUMO was probably more significant than the high energy level of 
the HOMO.  The high HOMO orbital is a trait that would be seen if the enzyme was 
acting as a base, but it does not seem to apply to these compounds with an electron-
deficient nitrogen as its active center.  However, the higher energy of the LUMO may 
suggest that the inhibitor is accepting electrons from the enzyme. Another possible 
explanation is that the higher the energy of the LUMO results in a weaker solvent shell 
around the molecule, easing the way to exclude water for a stronger interaction with the 
enzyme. 
 
Considerations for Future PL74 SAR 
 This author believes that it is quite possible that PL74 is acting as a choline 
analog, thereby possibly inhibiting phospholipid synthesis in the P. falciparum parasite.    
Dr. Vial’s research suggests that the mono-quaternary compounds inhibit the choline 
transport from the plasma into the erythrocyte, so this would be the first possible site of 
action to investigate for PL74.  The diphenylmethylpiperazine headgroup on PL74 was in 
fact added to the molecule for the purpose of inhibiting PfCRT (which is a transporter) so 
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it may be that this moiety is also effective in the inhibition of the erythrocytic choline 
transporter.  From the results of the SAR presented in this dissertation, it can be seen that 
the activity is dependent on the whole headgroup; the removal of a single phenyl ring was 
not tolerated. 
 If PL74 is a choline synthesis inhibitor, it is a unique one.  It is interesting that in 
Dr. Vial’s study that they found that a 10-to-12 carbon chain was essential for strong 
activity.  PL74 does not have the “essential” long chain.  Also, Dr. Vial suggests that the 
optimum volume for the head group was about 200-400 Å3;  If PL74 is considered a 
chain-less headgroup, where the whole molecule is considered headgroup, then it is much 
larger than the suggested dimensions.  Also, there are some pyridinium compounds 
among Dr. Vial’s analogs but no 4-aminopyridine compounds.  In fact, in a search 
conducted for analogous compounds in the literature, this author did not find any 
antimalarial choline analogs that were 4-aminopyridiniums.  If PL74 is acting as a 
choline analog inhibiting phospholipid synthesis, then it would be novel in structure, and 
this might indicate a new mode of action.  The shape of the molecule, and the clues from 
the SAR as an inverse map of an unknown active site, seem to indicate that it would bind 
to an active site shaped differently than the site hypothesized by the Vial group based on 
the shape of their active analogs. 
 Nevertheless, the large increase in activity for the bis-quaternary compounds 
compared to the mono-compounds, makes this researcher wonder if PL74 is half of a 
great antimalarial drug.  Bis-PL74 analogs might lead to a fruitful class of molecules for 
SAR exploration. 
65 
 
 The work of Campos and Espinosa is of interest because their analogs are 4-
aminopyridiniums applied to the inhibition of human phospholipid synthesis.  The use of 
molecular orbital modeling to look deeper into the trends seen, as the SAR of PL74 is 
expanded, could be a beneficial addition.  Also, the work they have done in finding 
substituents that increase the electron donation of the amine would also be useful to 
consider using in designing future PL74 analogs. 
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Chapter 6 
 
Summary and Conclusion 
 
Malaria is an on-going tragedy, taking too many lives and locking people, 
communities, and even nations into poverty and hopelessness.  The goal to eradicate 
malaria is certainly an honorable goal and hopefully achievable.  To intervene and change 
this situation, it will take everyone working together:  Charitable people donating ITNs 
for those who need them but cannot afford to buy them; scientists doing ingenious 
science in pursuit of vaccines, producing the best vaccines possible; organizations 
tracking resistance, making deployment policies, and evaluating the actions that are being 
taken.  But at the center of this campaign there has to be a continuous stream of safe, 
affordable, curative drugs to save lives and decrease the opportunity for transmission of 
the malaria parasites, staying at least one drug ahead of resistant strains. 
The Peyton Lab Reversed-CQ project shows promise of being able to produce a 
safe, inexpensive, effective antimalarial drug that can be of use in the effort to eradicate 
malaria.  By functionalizing CQ with an RA moiety the resistance mechanism can be 
overcome, as demonstrated by the in vitro and in vivo activity of the prototype molecule, 
PL01.   
PL74 was first thought to be a minimal version of a Reversed-CQ compound and 
an SAR study was pursued in hope that the activity could be optimized.  During this 
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work, it was discovered that the structure originally assumed for PL74 was incorrect and 
that PL74 is a pyridinium salt.   
In the SAR study there are two findings that indicate a different mode of action 
for PL74.  The intolerance of the removal of a phenyl group from the RA portion of the 
molecule, revealed by the inactivity of analog PL238 in contrast with compounds made 
by Steve Burgess and Bornface Gunsaru, showed a drastic departure from Reversed-CQ 
behavior.  The antimalarial activity of PL167, with 3-aminopyridine attached to the RA 
group via an amine linkage, was unexpected; in addition, the inactivity of PL360, the 
CQ-mimic, and PL169, with 2-aminopyridine attached to the RA group via an amine 
linkage, was unexpected.  These results are opposite the behavior predicted by earlier 
aminoquinoline work reported by Egan.  The overall message from this SAR is that PL74 
is not like the Reversed-CQ compounds and the hope is that these indications are pointing 
to not only a different, but a useful, antimalarial mechanism. 
A review of the literature found that quaternary ammonium salts, including 
pyridinium salts, are often biologically active molecules and often operate as choline 
analogs.  Two case studies were reviewed, one looking at Dr. Henri Vial’s work with 
antimalarial choline analogs and the second looking at Campos/Espinosa’s work on 
anticancer choline analogs.  In both lines of research it was found that the bis-quaternary 
drugs were significantly more active than the mono-compounds, and, in both cases, these 
compounds exerted their cytotoxic action by inhibition in the phosphatidylcholine 
biosynthesis pathway.  The literature study uncovered a wealth of ideas and methods for 
future investigations into the antimalarial action of PL74. 
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 Additional SAR study for PL74 is needed in two directions.  The optimization of 
the antimalarial activity of PL74 may be possible through the addition of electron-
donating substituents both on the amine substituent and on the ring.  Also, the design and 
synthesis of bis-PL74 compounds seems to be an important next step for this research.   
Using molecular orbital calculations in the design of analogs may bring more clarity to 
the process.  The exploration of the mode of action of PL74 should be continued because 
of the great need for more antimalarial drugs and because there is a possibility that this 
research could lead to an effective antimalarial drug. 
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Chapter 7 
 
 
Experimental Methods 
 
 
All names were generated using ChemBioDraw Ultra 13.0.  Purities were analyzed using 
a Varian Prostar Binary HPLC system, measuring by UV detection at 254 and 325 nm, 
using a Varian ProStar 325 UV/Vis dual wavelength detector using Method 2.  Method 2 
was done with Supelco Ascentis C18 column (15 cm x 4.6 cm, 5 µm pore size), from 
99:5 water/acetonitrile with 0.1% formic acid in both to 30:70, at 1 mL/min, over 10 
minutes.  High resolution accurate mass data was generated by injecting 
samples into methanol:water at a flow rate of 0.2ml/min directed to a Thermo LTQ-
Orbitrap XL Discovery max spectrometer (San Jose, CA, USA) equipped with an ESI ion 
max source. The ionization interface was operated in the positive mode using the 
following settings: source voltage, 4 kV; sheath and aux gas flow rates, 20 and 5 units 
respectively; tube lens voltage, 90 V; capillary voltage, 50 V; and capillary temperature, 
300°C. The Orbitrap mass analyzer was externally calibrated prior to analysis to obtain 
mass accuracy within ± 2-3 ppm.  1H, 13C and 2D NMR experiments were run on a 
Bruker 600MHz AVANCE-III instrument, using the standard pulse sequences provided, 
including zg30, zgpg30, cosygpqf, hsqcetgpsi2, hmbcgplpndqf, and noesyph, at 25°C. 
 
PL72:  2-(4-Benzhydrylpiperazin-1-yl)ethan-1-ol 
1-(2-Hydroxyethyl)piperazine (2.0 g, 15.4 mmol) was dissolved in DMF (20 mL).  
K2CO3 (4.27 g, 3.1 mmol) and KI (catalytic amount) were added.  The mixture was 
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stirred at room temperature while chlorodiphenylmethane (2.74 mL, 3.12 g, 15.4 mmol) 
was added dropwise.  The solution was stirred at room temperature for two hours and 
then heated to 76 oC for 22 hours.  The reaction solution was cooled to room temperature, 
diluted with distilled water (100 mL) and extracted with diethyl ether (3 x 20 mL).  The 
combined diethyl ether was washed with brine (30 mL), dried over MgSO4, and 
evaporated to give PL72 (3.39 g, 11.4 mmol, 74%). 
 
PL73:  1-Benyzhydryl-4-(2-chloroethyl)piperazine 
PL72 (1.13 g, 3.8 mmol) was dissolved in chloroform (10 mL).  DMF (2 drops) and 
thionyl chloride (200 µL) was added and solution was refluxed with stirring for 1.5 
hours.  Additional thionyl chloride (400 µL) was added and the solution was refluxed for 
40 more minutes, during which a white precipitate formed.  The solid was collected by 
filtration, washed with diethyl ether and air dried to give PL73 (~1.34 g, 3.8 mmol, 
100%) and used without further purification. 
 
Alternate Synthesis of PL73:  Diphenylmethylpiperazine (25.21 g, 100 mmol) and K2CO3 
(27.98 g, 202 mmol) was stirred in 1,2-dichloroethane (85.0 mL, 106 g, 1.1 mol) and 
heated to 80oC for 48 hours.  The reaction mixture was cooled to room temperature and 
partitioned between water and CHCl3.  The CHCl3 solution was evaporated down to 
brown clay.  The brown clay was separated on a silica column (40 g) with ethyl acetate 
eluent to give PL73 (4.63g, 13.2 mmol, 13%). 
 
71 
 
PL74: 4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)ethyl]pyridinium chloride 
PL73 (1.34 g, 3.8 mmol) and 4-aminopyridine (0.53 g, 5.6 mmol) were stirred into EtOH 
(15 mL) and refluxed for 21 hours.  The reaction solution was condensed to half volume 
by evaporation and the resulting white precipitate was collected by filtration, washed 
with chilled EtOH and then with diethyl ether, and air dried to yield PL74 (0.49 g, 1.2 
mmol, 32%) as a white solid.  HPLC (Method 2) tR=5.72 min (99% pure).  MS(ESI): 
m/z=373.2385 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 8.03 (2 H, d, J = 7.22 Hz), 
7.41-7.41 (4 H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.16 (2 H, t, J = 7.36 Hz), 6.79 (2 H, d, J = 
7.23 Hz), 4.15-4.20 (3 H, m), 2.74 (2 H, t, J = 5.79 Hz), 2.53 (4 H, s), 2.38 (3 H, br s).  
13C NMR δ (ppm)(600 MHz, CH3OH-d4): 160.8, 144.5, 144.1, 129.5, 129.0, 128.1, 
110.3, 77.8, 58.8, 56.0, 54.3, 53.2. 
 
PL76: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-phenylamine 
PL73 (1.00 g, 3.4 mmol) and aniline (0.05 mL, 0.05 g, 0.54 mmol) was stirred together in 
EtOH (3 ml) and microwave heated to 130 oC for 15 minutes.   Two more additions of 
aniline (each 0.1 mL, 0.1 g, 1.1 mmol) were added and the reaction was microwave 
heated to 130 oC for 15 minutes after each addition. The solvent was evaporated and the 
solid was purified on alumina with hexane/EtOAc gradient to 100% EtOAc, yielding 
PL76 (0.03 g, 0.08 mmol, 3 %).  HPLC (Method 2) tR=9.41 min (85% pure).  MS(ESI): 
m/z=372.4342 (M+).  13C NMR δ (ppm)(CHCl3-d): 148.6, 142.8, 129.2, 128.5, 128.4, 
127.9, 126.9, 126.9, 117.2, 112.9, 77.5, 76.3, 57.9, 56.7, 54.0, 53.2, 51.9, 51.8, 40.3, 1.0 
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PL165: 4-Amino-1-[2-(4-benzhydryl-piperazin-1-yl)-acetyl]-pyridinium chloride 
PL170 (0.66 g, 3.2 mmol) and diphenylmethylpiperazine (1.20 g, 4.8 mmol) were stirred 
together in EtOH (3 mL) and microwave heated to 103 oC for 15 minutes.  The solvent 
was evaporated and the solid product was purified on a basic alumina column with a 
EtOAc/MeOH gradient to 30% MeOH, yielding PL165 (0.51 g, 1.2 mmol, 38 %).  HPLC 
(Method 2) tR=7.31 min (92% pure). MS(ESI): m/z=387.2179 (M+). 1H NMR δ 
(ppm)(600 MHz, CH3OH-d4): 8.41 (2 H, dd, J = 4.99, 1.63 Hz), 7.70 (2 H, dd, J = 5.01, 
1.65 Hz), 7.47 (4 H, d, J = 7.73 Hz), 7.29 (4 H, t, J = 7.60 Hz), 7.19 (2 H, t, J = 7.37 Hz), 
4.30 (1 H, s), 3.25 (2 H, s), 2.67 (4 H, s), 2.53 (4 H, br s).  13C NMR δ (ppm)(CH3OH-d4): 
13C NMR δ (ppm)(CH3OH-d4):  171.8, 150.9, 147.5, 144.1, 129.6, 129.0, 128.1, 115.2, 
77.7, 62.9, 54.6, 52.9. 
 
PL166: 2-(4-Benzhydrylpiperazin-1-yl)-N-pyridin-3-yl-acetamide 
PL171 (1.71 g, 10.0 mmol), Diphenylmethylpiperazine (2.88 g, 11.4 mmol), K2CO3 (2.11 
g, 15.2 mmol), and KI (1.80 g, 10.8 mmol) were stirred in DMF (60 mL) and refluxed for 
24 hours at 60 oC.  The reaction mixture was cooled, diluted with water and extracted 
with DCM. The DCM was evaporated and the resulting dark oil was purified on an 
alumina column with EtOAc eluent, yielding PL166 (2.33 g, 6.0 mmol, 60%). 
 
PL167: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-3-yl-amine 
PL166 (2.5 g, 6.5 mmol) was dissolved in DCM (30 mL) and chilled to 0 oC.  Then 1 M 
LiAlH in THF(3 mL) was added dropwise.  The solution was stirred at 0 oC for one hour 
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and then at room temperature for 18 hours.  The reaction was followed by TLC.  The 
solution was again chilled to 0 oC, then  1 M LiAlH4 in THF (2 mL) 2 was added and the 
mixture was stirred for 1 hour at 0 oC and then at room temperature for 48 hours.   The 
reaction was diluted with water and extracted with EtOAc, yielding PL167, (trace 
amount). HPLC (Method 2) tR=6.24 min (96% pure). MS(ESI): m/z=373.2385 (M+). 1H 
NMR δ (ppm)(600 MHz, CH3OH-d4): 7.81 (1 H, d, J = 2.86 Hz), 7.64 (1 H, dd, J = 4.71, 
1.33 Hz), 7.31-7.35 (4 H, m), 7.16 (4 H, t, J = 7.61 Hz), 7.03-7.09 (3 H, m), 6.92 (1 H, 
ddd, J = 8.38, 2.88, 1.34 Hz), 4.14 (1 H, s), 3.14 (2 H, s), 2.52 (2H, t, J = 6.77 Hz), 2.47 
(4 H, br s), 2.36 (4 H, br s).  13C NMR δ (ppm)(600 MHz, CH3OH-d4): 146.9, 144.1, 
137.7, 135.7, 129.6, 129.0, 128.1, 125.5, 120.1, 77.8, 58.0, 54.5, 52.8, 41.0. 
 
PL168: 2-(4-Benzhydrylpiperazin-1-yl)-N-pyridin-2-yl-acetamide 
PL172 (1.72 g, 6.5 mmol), diphenylmethylpiperazine (2.87 g, 11.4 mmol), K2CO3 (2.12 
g, 15.4 mmol), and KI (1.75 g, 12 mmol) were stirred in DMF (50 mL) and refluxed for 
24 hours at 60 oC.  The reaction mixture was cooled, diluted with water and extracted 
with DCM.  The DCM was evaporated and the resulting thick oil was purified on an 
alumina column with 50%EtOAc/50% hexane eluent, yielding PL168 (1.73 g, 4.48 
mmol, 69%). 
 
PL169: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-2-yl-amine 
PL 168 (0.67 g, 1.7 mmol) was dissolved in THF (12 mL) and added dropwise into a 1 M 
LiAlH4 in THF solution (3.6 mL) which was chilled to 0 oC.  The reaction was stirred on 
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ice for 15 minutes, then stirred at room temperature for 18 hours.  The reaction was 
quenched with the addition of EtOAc (5 mL), then water (10 mL), then 2 M NaOH (1 
mL). The reaction solution was diluted with water (30 mL) and extracted with EtOAc and 
purified on Alumina with EtOAc, yielding PL169 (0.60 g, 1.6 mmol, 95%).  HPLC 
(Method 2) tR=6.68 min (76% pure). MS(ESI): m/z=373.2386 (M+). 1H NMR δ 
(ppm)(600 MHz, CH3OH-d4): 7.92-7.93 (1 H, m), 7.46 (5 H, d, J = 7.75 Hz), 7.29 (4 H, t, 
J = 7.62 Hz), 7.19 (2 H, t, J = 7.37 Hz), 6.54-6.55 (2 H, m), 4.27 (1 H, s), 3.42 (2 H, t, J = 
6.62 Hz), 2.65 (3 H, s), 2.54-2.54 (8 H, br m).  13C NMR δ (ppm)(600 MHz, CH3OH-d4): 
13C NMR δ (ppm)(CH3OH-d4): 148.0, 144.1, 138.9, 129.6, 129.5, 129.0, 128.1, 113.4, 
78.1, 77.8, 58.3, 54.4, 52.8, 39.5. 
 
PL170:  4-Amino-1-(2-chloroacetyl)pyridinium chloride 
4-Aminopyridine (2.65 g, 28.0 mmol) and K2CO3 (5.80 g, 41.7 mmol) was dissolved in 
DCM (75 mL).  Chloroacetylchloride (3.5 ml) was added dropwise and the solution was 
stirred and refluxed for 4 hours.  The reaction solution was diluted with 200 mL of ice 
water and the resulting precipitate was filtered and air dried, yielding PL170 (1.00 g, 4.8 
mmol, 17%).  PL170 was used without further purification. 
 
PL171:  2-Chloro-N-pyridin-3-ylacetamide 
3-Aminopyridine (2.83 g, 30.1 mmol) was dissolved in DCM (100 mL).  
Chloroacetylchloride (3.5 ml) was added dropwise and the solution was stirred at room 
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temperature for three days.  The solid was filtered, washed with DCM and air dried, 
yielding PL 171 (5.98 g, 34.8 mmol, 86%), which was used without further purification. 
 
PL172:  2-Chloro-N-pyridin-2-ylacetamide 
2-Aminopyridine (2.84 g, 30.2 mmol) was dissolved in DCM (100 mL).  
Chloroacetylchloride (3.5 ml) was added dropwise and the solution was stirred at room 
temperature for three days.  The solid was filtered, washed with DCM and air dried, 
yielding PL 172 (4.41 g, 25.7 mmol, 85%), which was used without further purification. 
 
PL215: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-pyridin-4-ylmethylamine 
PL373 (3.37 g, 11.4 mmol) and 4-pyridine carboxaldehyde (2.5 mL, 2.2 g, 14.7 mmol) 
were stirred together with MgSO4 in toluene  at room temperature for 48 hours.  The 
solution was filtered and then the solvent evaporated.  The solid was taken up in MeOH .  
NaBH4 (0.88 g) was added and the solution was stirred for 4 days.  The reaction was 
quenched with water, the product was extracted CHCl3 and then the solvent was 
evaporated.  The solid was purified on a basic alumina column with a 20%MeOH/80% 
EtOAc eluent, yielding PL215 (1.14 g, 2.95 mmol, 26 %).  HPLC (Method 2) tR=4.67 
min (87% pure).  MS(ESI): m/z=387.2544 (M+).  1H NMR δ (ppm)(600 MHz, CH3OH-
d4): 1H NMR δ (ppm)(CH3OH-d4): 8.46 (2 H, d, J = 5.29 Hz), 7.41 (6 H, t, J = 7.56 Hz), 
7.26 (4 H, t, J = 7.55 Hz), 7.17 (2 H, d, J = 7.42 Hz), 4.22 (1 H, s), 3.82 (2 H, s), 2.70 (2 
H, t, J = 6.72 Hz), 2.53 (3 H, t, J = 6.94 Hz). 13C NMR δ (ppm)(CH3OH-d4): 150.2, 
144.0, 129.6, 129.0, 128.1, 125.0, 125.0, 77.7, 58.2, 54.5, 53.0, 52.7, 46.2. 
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PL232:  4-Amino-1-ethyl-pyridinium chloride 
4-Aminopyridine (1.0 g, 10.6 mmol) and acetylchloride (7.6 mL, 6.9 g, 88 mmol) were 
dissolved into DCM and stirred at room temperature for 12 hours. The reaction mixture 
was filtered and the solids were washed with DCM and then purified on a silica column 
with an eluent mix of 90%
 
CHCl3/10% MeOH.  The resulting solid was dissolved in THF 
(8 mL) and added dropwise to a chilled solution of 1 M LiAlH4 in THF (3 mL) which had 
been chilled to 0 oC.   The reaction was stirred for 1 hour at 0 oC and then for 24 hours at 
room temperature.  The reaction was quenched with water, the solvent was evaporated, 
and the residue was purified on silica column with an eluent mix of 90%
 
CHCl3/10% 
MeOH, yielding PL232 (0.06 g, 0.38 mmol, 3.6%).  HPLC (Method 2) tR=1.49 min (85% 
pure). MS(ESI): m/z=123.09128 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 7.98 (2 
H, d, J = 5.77 Hz), 6.54 (2 H, dd, J = 5.32, 1.61 Hz), 3.20 (2 H, q, J = 7.22 Hz), 1.26 (3 H, 
t, J = 7.22 Hz).  
 
PL236:  4-Amino-1-[2-(4-methyl-piperazin-1-yl)-ethyl]-pyridinium chloride 
4-Aminopyridine (1.05 g, 11.2 mmol), 1,2-dichloroethane (8.0 mL, 6.4 g, 64 mmol) and 
Et3N (0.5 mL, 0.7 g, 6.8 mmol) were stirred together and microwave heated to 120 oC for 
15 minutes. The reaction was cooled to 0 oC and filtered. The filtrate was evaporated, and 
the residue was stirred in to 1-methylpiperazine (6.0 ml, 6.6g, 67 mmol) and heated to 95 
oC for 26 hours.  The reaction mixture was cooled, diluted with MeOH and filtered.  The 
filtrate was evaporated and the residue was purified on a basic alumina column with a 
EtOAc/MeOH gradient to 20% MeOH, yielding PL236 (0.13g, 0.51 mmol, 4.5%).  
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HPLC (Method 2) tR=1.19 min (100% pure).  MS(ESI): m/z=221.17657 (M+). 1H NMR δ 
(ppm)(600 MHz, CH3OH-d4): 8.08 (2 H, m), 6.84 (2 H, m), 4.23 (2 H, t, J = 5.74 Hz), 
2.78 (2 H, t, J = 5.75 Hz), 2.51-2.54 (8 H, br m), 2.29 (3 H, s). 13C NMR δ (ppm)(600 
MHz, CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 161.6, 145.3, 111.2, 59.5, 56.8, 54.3, 
46.8. 
 
PL238:  4-Amino-1-[2-(4-benzyl-piperazin-1-yl)-ethyl]-pyridinium chloride 
PL364 (0.58 g, 1.7 mmol) was dissolved in anhydrous THF (30 mL) and chilled to 0 oC.  
1M LiAlH4 in THF (2.8 ml, 2.8 mmol LiAlH4) was added dropwise with stirring for 1 
hour and then at room temperature for 12 hours.  More 1 M LiAlH4 in THF (4.0 ml, 4.0 
mmol LiAlH4) was added and the reaction was stirred at 60 oC for 12 hours.  The reaction 
was quenched with EtOAc (10 mL) , and then water (30 mL).  The product was extracted 
from the quenched reaction with EtOAc (6x, 300 mL total).  The EtOAc was evaporated  
and the resulting residue was purified on a basic alumina column with EtOAc/MeOH 
gradient to 40% MeOH, yielding PL238, (0.29 g, 0.87 mmol, 51%).  HPLC (Method 2) 
tR=1.50 min (89% pure).  MS(ESI): m/z=297.20771 (M+). 1H NMR δ (ppm)(600 MHz, 
CH3OH-d4):  1H NMR δ (ppm)(CH3OH-d4): 8.00 (2 H, d, J = 5.83 Hz), 7.34-7.36 (4 H, 
m), 7.27-7.31 (1 H, m), 6.58 (2 H, dd, J = 5.35, 1.64 Hz), 3.57 (2 H, s), 3.31 (2 H, t, J = 
6.75 Hz), 2.63 (2 H, t, J = 6.76 Hz), 2.56-2.58 (8 H, br m).   13C NMR δ (ppm)(600 MHz, 
CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 158.3, 146.3, 144.1, 143.3, 129.6, 129.0, 
128.1, 110.0, 104.8, 77.8, 58.6, 56.3, 54.2, 53.3. 
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PL240: 4-amino-1-[2-(4-benzhydryl-piperazin-1-yl)-2-oxo-ethyl]-pyridinium 
chloride  
Diphenylmethylpiperazine (2.52 g, 10.0 mmol) and K2CO3 (2.83 g, 20.0 mmol) were 
slurried in DCM (50 mL).  Chloroacetyl chloride  (2.4 mL, 3.4 g, 30 mmol) was added 
slowly and stirred at room temp for 12 hours.   The reaction mixture was partitioned 
between DCM and water.  The DCM solution was dried over MgSO4 and then the solvent 
was evaporated to yield a thick oil.  The oil and 4-aminopyridine (0.94 g, 10 mmol) were 
stirred in EtOH (100 mL) and heated to 90 oC for 12 hours.  The solvent was evaporated 
and the resulting oil was purified on basic alumina with an ethylactetate/methanol 
gradient to 40% methanol to yield PL240 (3.04 g, 7.2 mmol, 72%). HPLC (Method 2) 
tR=7.74 min (97% pure). MS(ESI): m/z=387.21776 (M+). 1H NMR δ (ppm)(600 MHz, 
CH3OH-d4): 7.92-7.94 (2 H, m), 7.49-7.49 (5 H, m), 7.32 (5 H, t, J = 7.62 Hz), 7.23 (2 H, 
t, J = 7.38 Hz), 6.82-6.87 (2 H, m), 5.19 (2 H, s), 4.36 (1 H, s), 3.64 (2 H, t, J = 4.94 Hz), 
3.57 (2 H, t, J = 4.91 Hz), 2.54 (2 H, t, J = 4.85 Hz), 2.45 (2 H, t, J = 5.00 Hz).  13C NMR 
δ (ppm)(CH3OH-d4):  13C NMR δ (ppm)(CH3OH-d4): 166.0, 161.1, 145.4, 143.6, 129.7, 
129.0, 128.3, 110.3, 77.2, 52.8, 52.5, 49.6, 46.0, 43.7. 
 
PL297:  4-Amino-1-[2-(4-benzyl-piperidin-1-yl)-ethyl]-pyridinium 
PL170 (0.65 g, 3.1 mmol) and 4-benzylpiperidine (0.58 mL, 0.58 g, 5.7 mmol) and 
K2CO3 (1.14 g, 8.2 mmol) were stirred together in DMF and room temperature for 2 
weeks.  The solution was filtered and evaporated, resulting in an oily residue.  The 
residue was dissolved in THF (25 mL) and 1 M LiAlH4 in THF (0.6 mL was added; the 
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solution was stirred at room temperature for 12 hours.   The reaction was quenched with 
EtOAc , then with water, and then cooled to room temperature.  The product was 
extracted with EtOAc (4x, 300 mL total).  The solvent was evaporated and the resulting 
oil was purified on a silica column with 30% MeOH/70% EtOAc, yielding PL297 (0.13 
g, 0.39 mmol, 13 %).  HPLC (Method 2) tR=1.5 min (55% pure).  MS(ESI): m/z=xxx 
(M+).  
 
PL324:  4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-2-methylpyridinium 
chloride 
PL73 (1.57 g, 5.0 mmol) and 4-amino-2-methylpyridine (0.54 g, 5.0 mmol) were stirred 
into EtOH (10 mL) and microwave heated to 100 oC  for 15 minutes.  The solvent was 
evaporated and the residue was columned on a basic alumina column with an 
ethylacetate/methanol gradient to 20% methanol, to yield PL324 (0.83 g, 2.0 mmol, 40% 
yield).  HPLC (Method 2) tR=5.65 min (98% pure).  MS(ESI): m/z=387.2544 (M+). 1H 
NMR (ppm)(600 MHz, CH3OH-d4): 7.96 (1 H, d, J = 6.93 Hz), 7.41 (4 H, d, J = 7.68 
Hz), 7.25 (4 H, t, J = 7.61 Hz), 7.17 (2 H, d, J = 7.39 Hz), 6.67-6.71 (2 H, m), 4.18-4.20 
(3 H, m), 2.72 (2 H, t, J = 5.95 Hz), 2.30-2.61 (11 H, m).  13C NMR δ (ppm)(CH3OH-d4): 
13C NMR δ (ppm)(CH3OH-d4): 160.8, 153.7, 145.8, 144.1, 129.6, 129.0, 128.1, 111.3, 
109.2, 77.8, 58.4, 54.6, 53.2, 52.5, 19.9. 
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PL325:  4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-3-methylpyridinium 
chloride 
PL73 (1.56 g, 5.0 mmol) and 4-amino-3-methylpyridine (0.54 g, 5.0 mmol) were stirred 
together in EtOH (10 ml) and microwave heated to 100 oC for 15 minutes. The solvent 
was evaporated and the residue was columned on a basic alumina column with an 
ethylacetate/methanol gradient to 30% methanol, to yield PL325 (1.48 g, 3.5 mmol, 70% 
yield). HPLC (Method 2) tR=5.86 min (99% pure). MS(ESI): m/z=287.2543 (M+). 1H 
NMR (ppm)(600 MHz, CH3OH-d4): 7.97-7.98 (2 H, m), 7.41 (4 H, d, J = 7.69 Hz), 7.25 
(4 H, t, J = 7.55 Hz), 7.17 (2 H, d, J = 7.40 Hz), 6.80 (1 H, d, J = 7.03 Hz), 4.17-4.18 (3 
H, m), 2.74 (2 H, t, J = 5.85 Hz), 2.53 (4 H, s), 2.38 (3 H, br s), 2.16 (3 H, s).  13C NMR δ 
(ppm)(CH3OH-d4): 144.1, 143.0, 142.7, 129.6, 129.0, 128.1, 109.5, 77.7, 58.8, 56.0, 54.3, 
53.2, 14.4. 
 
PL327:  4-Amino-1-[2-(4-benzhydrylpiperazin-1-yl)-ethyl]-2-methoxypyridinium 
chloride 
PL73 (0.96 g, 3.1 mmol) and 4-amino-2-bromopyridine (0.52 g, 3.0 mmol) were stirred 
together in EtOH (3 mL) and microwave heated to 100 oC for 10 minutes.  The solvent 
was evaporated and the residue was columned on a basic alumina column with an 
ethylactate/methanol gradient to 30% ethanol to yield PL327 (mass not recorded).  HPLC 
(Method 2) tR=5.85 min (96% pure).  MS(ESI): m/z=403.2492 (M+). 1H NMR (ppm)(600 
MHz, CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 7.75 (1 H, d, J = 7.34 Hz), 7.41-7.41 (4 
H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.17 (2 H, d, J = 7.37 Hz), 6.49 (1 H, dd, J = 7.33, 2.34 
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Hz), 6.28 (1 H, d, J = 2.34 Hz), 4.20 (1 H, s), 4.15 (2 H, t, J = 6.13 Hz), 4.05 (3 H, s), 
2.67 (2 H, t, J = 6.14 Hz), 2.54 (5 H, s), 2.38 (3 H, br s).   13C NMR δ (ppm) (600 MHz, 
CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 201.5, 163.3, 161.3, 144.1, 143.4, 129.6, 
129.0, 128.1, 105.7, 89.7, 77.8, 58.5, 57.7, 54.4, 53.1. 
 
PL328: 4-Amino-1-[2-(4-benzhydryl-piperazin-1-yl)-ethyl]-3-bromo-pyridinium 
chloride  
PL73 (1.05 g, 3.3 mmol) and 4-amino-3-bromopyridine (0.51 g, 3.0 mmol) were stirred 
together in EtOH (3 mL) and microwave heated to 100 oC for 10 minutes.  The solvent 
was evaporated and the residue was columned on a basic alumina column with an 
ethylactate/methanol gradient to 30% ethanol to yield PL328 (0.85g, 1.7 mmol, 52%).  
HPLC (Method 2) tR=5.82 min (97% pure). MS(ESI): m/z=451.1497 (M+). 1H NMR 
(ppm) (600 MHz, CH3OH-d4):  1H NMR δ (ppm)(CH3OH-d4): 8.57 (1 H, d, J = 1.70 Hz), 
8.09 (1 H, dd, J = 7.16, 1.73 Hz), 7.39-7.43 (4 H, m), 7.26 (4 H, t, J = 7.61 Hz), 7.16 (2 
H, t, J = 7.36 Hz), 6.94 (1 H, d, J = 7.14 Hz), 4.21-4.22 (3 H, m), 2.75 (2 H, t, J = 5.67 
Hz), 2.54 (5 H, s), 2.38 (3 H, br s).  13C NMR δ (ppm) (600 MHz, CH3OH-d4): 13C NMR 
δ (ppm)(CH3OH-d4): 158.3, 146.3, 144.1, 143.3, 129.6, 129.0, 128.1, 110.0, 104.8, 77.8, 
58.6, 56.3, 54.2, 53.3. 
 
PL 329: N-[2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-isonicotinamide 
PL73 (4.17 g, 13.2 mmol) and Huing’s base (5 mL) were dissolved in CHCl3 (150 mL).  
Nicotinoyl chloride (3.0 g, 17 mmol) was added in small portions and the reaction was 
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stirred for five days.  The solution was filtered, washed with saturated NaHCO3 solution 
(1x), washed with water (4x), and then the solvent was evaporated.  The solid was 
purified on Alumina column with EtOAC/MeOH gradient to 30% MeOH, yielding  
PL329 (0.67 g, 1.7 mmol, 13 %). HPLC (Method 2) tR=7.73 min (92% pure).  MS(ESI): 
m/z=401.2338 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 8.68 (2 H, dd, J = 4.68, 
1.61 Hz), 7.76 (2 H, dd, J = 4.60, 1.65 Hz), 7.42 (4 H, d, J = 7.68 Hz), 7.26 (4 H, t, J = 
7.61 Hz), 7.16 (2 H, t, J = 7.37 Hz), 4.24 (1 H, s), 3.54 (2 H, t, J = 6.76 Hz), 2.42-2.75 
(10 H, br m).   
 
PL330:  1-[2-(4-Benzhydrylpiperazin-1-yl)-ethyl]pyrimidin-4-ylamine 
PL73 (1.05 g, 3.3 mmol) and 3-aminopyrimidine were stirred together in ethanol (5 mL) 
and microwave heated at 100 oC for 15 minutes.  The solid was filtered, then air dried, 
then columned on a basic alumina column with  EtOAc/MeOH gradient up to 40% 
MeOH, and followed by recrystallization in MeOH, yielding PL330 (.69 g, 1.6 mmol,  
51%).  HPLC (Method 2) tR=5.32 min (99% pure). MS(ESI): m/z=374.2339 (M+). 1H 
NMR δ (ppm)(CH3OH-d4): 8.57 (1 H, d, J = 1.88 Hz), 8.14 (1 H, dd, J = 7.45, 2.02 Hz), 
7.41 (4 H, d, J = 7.63 Hz), 7.26 (4 H, t, J = 7.56 Hz), 7.17 (2 H, d, J = 7.32 Hz), 6.74 (1 
H, d, J = 7.45 Hz), 4.20 (1 H, s), 4.17 (2 H, t, J = 5.55 Hz), 2.74 (2 H, t, J = 5.56 Hz), 
2.55 (4 H, s), 2.38 (2 H, s).  13C NMR δ (ppm)(600 MHz, CH3OH-d4): 13C NMR δ 
(ppm)(CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 165.9, 155.2, 147.2, 144.1, 129.6, 
129.0, 128.1, 106.0, 77.8, 58.2, 54.2, 53.2, 53.1. 
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PL342:  1-[2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-4-methylamino-pyridinium 
chloride 
PL73 (0.89 g, 2.8 mmol) and 4-(methylamino)pyridine (0.30 g, 2.8 mmol) were stirred in 
EtOH (3 mL), then microwave heated to 130 oC for 15 minutes.  The solvent was 
evaporated and the residue was purified on a basic alumina column with EtOAc/MeOH 
gradient to 40% MeOH, yielding PL 342 (0.1 g, 0.24 mmol, 8.8%).  HPLC (Method 2) 
tR=5.80 min (99% pure). MS(ESI): m/z=387.2543 (M+). 1H NMR δ (ppm)(600 MHz, 
CH3OH-d4): 1H NMR δ (ppm)(CH3OH-d4): 8.13-8.14 (1 H, m), 7.97 (1 H, dd, J = 7.16, 
1.86 Hz), 7.41-7.41 (4 H, m), 7.25 (4 H, t, J = 7.61 Hz), 7.16 (2 H, t, J = 7.36 Hz), 6.80-
6.81 (2 H, m), 4.19 (3 H, t, J = 5.82 Hz), 2.97 (3 H, s), 2.74 (2 H, t, J = 5.79 Hz), 2.53 (4 
H, s), 2.38 (4 H, br s).  13C NMR δ (ppm)(600 MHz, CH3OH-d4):  159.5, 145.3, 144.1, 
142.8, 129.6, 129.0, 128.1, 111.4, 105.8, 77.8, 58.8, 55.9, 54.3, 53.2. 
 
PL343: [2-(4-Benzhydryl-piperazin-1-yl)-ethyl]-(3-nitro-pyridin-4-yl)-amine 
PL373 (1.05 g, 3.6 mmol) and 4-chloro-3-nitropyridine were slurried in water (4 mL) and 
microwave heated to 130 oC for 30 minutes.  The reaction mixture was diluted with 
additional water (100 mL) and extracted with EtOAc (3x; 300 mL total).  The EtOAc was 
evaporated and the residue was columned on basic alumina with EtOAc/MeOH gradient 
to 30% MeOH, yielding PL343 (0.69g, 1.7 mmol, 46 %).  HPLC (Method 2) tR=6.87 min 
(98% pure). MS(ESI): m/z=418.2241 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 
9.08 (1 H, s), 8.22 (1 H, d, J = 6.31 Hz), 7.46-7.48 (5 H, m), 7.29 (5 H, t, J = 7.62 Hz), 
7.19 (2 H, t, J = 7.36 Hz), 6.98 (1 H, d, J = 6.33 Hz), 4.27 (1 H, s), 3.51 (2 H, t, J = 6.34 
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Hz), 2.74 (2 H, t, J = 6.33 Hz), 2.62 (4 H, br s), 2.50 (4 H, br s).  13C NMR δ 
(ppm)(CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 152.9, 150.1, 149.1, 144.2, 131.2, 
129.6, 129.0, 128.1, 110.1, 77.9, 56.4, 54.1, 53.2, 40.2. 
 
PL350: 4-[2-(4-Benzhydryl-piperazin-1-yl)-ethylamino]-pyridin-3-ol  
PL343 (0.22 g, 0.53 mmol) was dissolved in MeOH and evaporated onto neutral 
Alumina.  FeCl3 (0.23 g, 1.4 mmol) and hydrazine monohydrate (2.5 mL, 2.4 g, 48.5 
mmol ) was ground into the alumina.  The alumina was loaded into a microwave vial and 
heated at 130% for 10 minutes.  The mixture was cooled, slurried in EtOAc and filtered 
through Celite.  The EtOAc was evaporated down to a thick oil.  The oil was brought up 
in dry THF and added dropwise into a boiling solution of dry THF (10 mL) with isoamyl 
nitrite (0.1 mL).  The solution was stirred and refluxed for 4 hours, then evaporated down 
to oil and purified on an alumina column with EtOAc/MeOH gradient, yielding the 
hydroxide side product (mass not recorded ). HPLC (Method 2) tR=7.59 min (92% pure).  
MS(ESI): m/z=388.29800 (M+).   
 
PL360:  1N,1N-Diethyl-4N-pyridin-4-ylpentane-1,4-diamine 
4-Chloropyridine (2.05 g, 21 mmol) was stirred into 2-amino-5-diethylaminopentane (20 
ml, 25 g, 155 mmol) and heated to 135 oC for 16 hours.  The excess solvent was distilled 
off using a short-path distillation apparatus and distilling up to 120 oC at 0.05 atm, 
leaving a brown residue.  The residue was separated on silica preparative TLC plates with 
an eluent mix of CHCl3:MeOH:NH4OH in 5:1:0.2 ratio, respectively.   The product was 
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found in a clear band at Rf =0.6.  The bands were collected, extracted off  the silica with 
the eluent solvent mix, and the solvent was evaporated, yielding a dark oil.  The oil was 
further purified on a silica column using a CHCl3 (with 2% Et3N )/MeOH (with 2% Et3N) 
gradient to 30% MeOH (with 2% Et3N ), yielding PL360 (0.01 g, 0.4 mmol, 0.2%).  
HPLC (Method 2) tR=1.45 min (99% pure). MS(ESI): m/z=236.21203 (M+). 1H NMR δ 
(ppm)(600 MHz, CH3OH-d4):  1H NMR δ (ppm)(CH3OH-d4): 7.84 (2 H, d, J = 5.80 Hz), 
6.42 (2 H, dd, J = 5.55, 1.55 Hz), 3.45-3.51 (1 H, m), 2.46 (4 H, q, J = 7.22 Hz), 2.37 (2 
H, d, J = 7.84 Hz), 1.40-1.50 (5 H, m), 1.09 (3 H, d, J = 6.40 Hz), 0.93 (6 H, t, J = 7.20 
Hz).  13C NMR δ (ppm)(CH3OH-d4): 155.9, 149.2, 108.6, 53.6, 49.6, 49.6, 48.4, 47.8, 
47.8, 35.5, 23.7, 20.7, 20.7, 11.1. 
 
PL350: 4-[2-(4-Benzhydryl-piperazin-1-yl)-ethylamino]-pyridin-3-ol  
PL343 (0.22 g, 0.53 mmol) was dissolved in MeOH and evaporated onto neutral 
Alumina.  FeCl3 (0.23 g, 1.4 mmol) and hydrazine monohydrate (2.5 mL, 2.4 g, 48.5 
mmol ) was ground into the alumina.  The alumina was loaded into a microwave vial and 
heated at 130% for 10 minutes.  The mixture was cooled, slurried in EtOAc and filtered 
through Celite.  The EtOAc was evaporated down to a thick oil.  The oil was brought up 
in dry THF and added dropwise into a boiling solution of dry THF (10 mL) with isoamyl 
nitrite (0.1 mL).  The solution was stirred and refluxed for 4 hours, then evaporated down 
to oil and purified on an alumina column with EtOAc/MeOH gradient, yielding the 
hydroxide side product (mass not recorded ). HPLC (Method 2) tR=7.59 min (92% pure).  
MS(ESI): m/z=388.29800 (M+).   
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PL364:  4-Amino-1-[2-(4-benzyl-piperazin-1-yl)-acetyl]-pyridinium chloride 
 Piperazine (13.07 g, 152 mmol) was dissolved in DCM (50 mL) and benzylbromide (6 
ml, 8.7 g, 50 mmol) was added in dropwise; the solution was stirred at room temperature 
for several days.  The reaction mixture was washed with water (6x, 300 mL total) and 
then the solvent was evaporated, yielding a white solid.  The entire amount of solid and 
K2CO3 (7.63g, 55.2 mmol) were stirred together in DMF (50 mL), then PL170 (5.93 g, 
28.6 mmol) was added and the mixture was stirred at 40 oC for 16 hours.  The reaction 
was cooled and filtered.  The solvent was evaporated and the residue was purified on a 
basic alumina column with CHCl3 eluent, yielding PL364 (0.58 g, 1.7 mmol, 5.9%).  
MS(ESI): m/z=311.18743 (M+). 1H NMR δ (ppm)(600 MHz, CH3OH-d4): 1H NMR δ 
(ppm)(CH3OH-d4): 8.42 (2 H, dd, J = 5.11, 1.62 Hz), 7.71 (2 H, dd, J = 5.05, 1.62 Hz), 
7.33-7.36 (4 H, m), 7.29-7.29 (1 H, m), 3.59 (2 H, s), 3.25 (2 H, s), 2.63 (8 H, br d, J = 
35.18 Hz).   13C NMR δ (ppm)(600 MHz, CH3OH-d4): 13C NMR δ (ppm)(CH3OH-d4): 
171.8, 150.9, 147.5, 138.4, 130.8, 129.4, 128.5, 115.2, 63.9, 62.9, 54.1, 53.8. 
 
PL373: 2-(4-Benzhydryl-piperazin-1-yl)-ethylamine 
Diphenylmethylpiperazine (1.31 g, 5.2 mmol), bromoethylphthalamide (1.29 g, 5.1 
mmol), K2CO3 (1.21 g, 8.8 mmol), and KI (.95 g, 5.8 mmol) were slurried in acetonitrile 
and microwave heated to 100 oC for 30 minutes.  The reaction mixture was cooled, 
diluted with CHCl3 and filtered.  The CHCl3 was evaporated leaving a thick oil.  The oil 
was stirred in MeOH and a white solid precipitated, which was filtered and air dried.  The 
white solid was slurried in EtOH.  Hydrazine monohydrate (27 mL) was added and the 
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mixture was refluxed for 8 hours, then cooled to room temperature and filtered.  The 
EtOH was evaporated yielding PL373, which was used without further purification. 
 
In vitro drug susceptibility assays63  
Both CQS (D6) and CQR (Dd2) P. falciparum maintained continuously in culture were 
used.103 Asynchronous cultures were diluted with uninfected RBCs and complete 
medium (RPMI-1640 with 0.5% Albumax II) to achieve 0.2% parasitemia and 2% 
hematocrit. In 96-well microplates, CQ (positive control) or RCQ diluted in complete 
medium from 10 mM stock in DMSO were added to the cell mixture to yield triplicate 
wells with drug concentrations ranging from 0 to 10-4 M in a final well volume of 100 
µL. After 72 h of incubation under standard culture conditions, plates were harvested and 
read by the SYBR Green I fluorescence-based method103 using a 96-well fluorescence 
plate reader (Gemini-EM, Molecular Devices), with excitation and emission wavelengths 
at 497 and 520 nm, respectively. The fluorescence readings were plotted against 
log[drug], and the IC50 values were obtained from curve fitting performed by nonlinear 
regression using either Prism (GraphPad) or Excel (Microsoft) software.   
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